10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-21-151704.txt : 20210505 0001193125-21-151704.hdr.sgml : 20210505 20210505160728 ACCESSION NUMBER: 0001193125-21-151704 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210505 DATE AS OF CHANGE: 20210505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DBV Technologies S.A. CENTRAL INDEX KEY: 0001613780 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36697 FILM NUMBER: 21893256 BUSINESS ADDRESS: STREET 1: 177-181 AVENUE PIERRE BROSSOLETTE CITY: MONTROUGE STATE: I0 ZIP: 92120 BUSINESS PHONE: 33(0)155427878 MAIL ADDRESS: STREET 1: 177-181 AVENUE PIERRE BROSSOLETTE CITY: MONTROUGE STATE: I0 ZIP: 92120 10-Q 1 d172290d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-36697

DBV TECHNOLOGIES S.A.

(Exact name of registrant as specified in its charter)


France		Not applicable
State or other jurisdiction of incorporation or organization		(I.R.S. Employer Identification No.)

177-181 avenue Pierre Brossolette Montrouge France		92120
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code +33 1 55 42 78 78

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
American Depositary Shares, each representing one-half of one ordinary share, nominal value €0.10 per share	DBVT	The Nasdaq Stock Market LLC
Ordinary shares, nominal value €0.10 per share*	n/a	The Nasdaq Stock Market LLC

*	Not for trading, but only in connection with the registration of the American Depositary Shares.

Securities registered pursuant to section 12(g) of the Act: None.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No

As of April 30, 2021, the registrant had 54,936,687 ordinary shares, nominal value €0.10 per share, outstanding.

Table of contents


		Page
Part I	Financial information		1
Item 1	Condensed Consolidated Statements of Financial Position (Unaudited) as of March 31,2021 and December 31, 2020		1
	Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) for the Three Months Ended March 31, 2021 and 2020		2
	Condensed Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2021 and 2020		3
	Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) for the Three Months Ended March 31, 2021 and 2020		4
	Notes to the Condensed Consolidated Financial Statements (Unaudited)		5
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations		13
Item 3	Quantitative and Qualitative Disclosures About Market Risk		17
Item 4	Controls and Procedures		17

Part II	Other information		18
Item 1	Legal Proceedings		18
Item 1A	Risk Factors		18
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds		18
Item 3	Defaults Upon Senior Securities		18
Item 4	Mine Safety Disclosures		18
Item 5	Other Information		18
Item 6	Exhibits		19

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS.

This Quarterly Report on Form 10-Q (“Form 10-Q”) contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. Forward-looking statements include statements, other than statements of historical fact, about, among other things:

•

statements regarding the impact of the ongoing COVID-19 pandemic and its effects on our operations, research and development and clinical trials and potential disruption in the operations and business of third-party manufacturers, contract research organizations, other service providers and collaborators with whom we conduct business;

•

our expectations regarding the timing or likelihood of regulatory filings and approvals, including with respect to our anticipated re-submission of a Biologics License Application for Viaskin^TM Peanut to the U.S. Food and Drug Administration;

•

the initiation, timing, progress and results of our pre-clinical studies and clinical trials, and our research and development programs;

•

the sufficiency of existing capital resources;

•

the implementation of our global restructuring plan, our business model and our other strategic plans for our business, product candidates and technology;

•

our ability to manufacture clinical and commercial supplies of our product candidates and comply with regulatory requirements related to the manufacturing of our product candidates;

•

our ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize Viaskin Peanut and/or our other product candidates, if approved;

•

the commercialization of our product candidates, if approved;

•

our expectations regarding the potential market size and the size of the patient populations for Viaskin Peanut and/or our other product candidates, if approved, and our ability to serve such markets;

•

the pricing and reimbursement of our product candidates, if approved;

•

the rate and degree of market acceptance of Viaskin Peanut and/or our other product candidates, if approved, by physicians, patients, third-party payors and others in the medical community;

•

our ability to advance product candidates into, and successfully complete, clinical trials;

•

the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

•

estimates of our expenses, future revenues, capital requirements and our needs for additional financing;

•

the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements;

•

our ability to maintain and establish collaborations or obtain additional grant funding;

•

our financial performance;

•

developments relating to our competitors and our industry, including competing therapies; and

•

other risks and uncertainties, including those listed under the caption “Risk Factors.”

Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, these statements are based on our estimates or projections of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our actual results, level of activity, performance, experience or achievements to differ materially from those expressed or implied by any forward-looking statement. These risks, uncertainties and other factors are described in greater detail under the caption “Risk Factors” in Part I. Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission (“SEC”) on March 17, 2021. As a result of the risks and uncertainties, the results or events indicated by the forward-looking statements may not occur. Undue reliance should not be placed on any forward-looking statement.

In addition, any forward-looking statement in this Annual Report represents our views only as of the date of this annual report and should not be relied upon as representing our views as of any subsequent date. We anticipate that subsequent events and developments may cause our views to change. Although we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, except as required by applicable law. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.

Part I – Financial Information

Item 1. Financial Statements

DBV Technologies S.A.

Condensed Consolidated Statements of Financial Position (unaudited)

(amounts in thousands, except share and per share data)


			March 31,			December 31,
	Note		2021			2020
Assets
Current assets :
Cash and cash equivalents		3	$	152,459		$	196,352
Trade receivables				—			2,230
Other current assets				7,349			8,792

Total current assets				159,809			207,375
Property, plant, and equipment, net				21,526			24,792
Right-of-use assets related to operating leases				9,168			10,104
Intangible assets				32			41
Other non-current assets				30,870			29,935

Total non-current assets				61,596			64,871

Total Assets			$	221,405		$	272,246

Liabilities and shareholders’ equity
Current liabilities:
Trade payables		4	$	17,176		$	20,338
Short-term operating leases				3,314			3,708
Short-term financial debt				701			724
Current contingencies		6		4,246			5,016
Other current liabilities		4		13,394			22,926

Total current liabilities				38,831			52,713

Long-term operating leases				9,533			10,496
Long-term financial debt				350			543
Non-current contingencies		6		2,229			2,527
Other non-current liabilities				1,286			475

Total non-current liabilities				13,398			14,042

Total Liabilities			$	52,229		$	66,754

Shareholders’ equity :
Ordinary shares, €0.10 par value; 54,936,687 and 54,929,187 shares authorized, and issued as at March 31, 2021 and December 31, 2020, respectively, and 4,100,663 and 4,029,763 shares outstanding as at March 31, 2021 and December 31, 2020, respectively			$	6,519		$	6,518
Additional paid-in capital				1,153,516			1,152,042
Treasury stock, 60,588 and 112,302 ordinary shares as of March 31, 2021 and December 31, 2020, respectively, at cost				(681	)		(1,169	)
Accumulated deficit				(987,992	)		(958,543	)
Accumulated other comprehensive income				399			484
Accumulated currency translation effect				(2,586	)		6,158

Total Shareholders’ equity			$	169,176		$	205,491

Total Liabilities and Shareholder’s equity			$	221,405		$	272,246

The accompanying notes are an integral part of these condensed consolidated financial statements.

DBV Technologies S.A.

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

(amounts in thousands, except share and per share data)


		Three Months Ended March 31,
	Note	2021			2020
Operating income	7	$	2,941		$	4,720

Operating expenses
Research and development expenses			(22,164	)		(27,532	)
Sales and marketing expenses			(729	)		(7,297	)
General and administrative expenses			(9,683	)		(11,113	)

Total Operating expenses			(32,575	)		(45,942	)

Loss from operations			(29,634	)		(41,222	)

Financial income			215			309

Loss before taxes			(29,419	)		(40,913	)

Income tax			(30	)		—

Net loss		$	(29,449	)	$	(40,913	)

Other comprehensive loss
Foreign currency translation differences, net of taxes			(8,744	)		(6,064	)
Actuarial (losses) gains on employee benefits, net of taxes			(85	)		189

Comprehensive loss		$	(38,279	)	$	(46,788	)

Basic/diluted Net loss per share attributable to shareholders	11	$	(0.54	)	$	(0.79	)

Weighted average shares outstanding used in computing per share amounts:			54,880,776			51,802,524

The accompanying notes are an integral part of these condensed consolidated financial statements.

DBV Technologies S.A.

Condensed Consolidated Statements of Cash Flows (unaudited)

(amounts in thousands)


			Three Months Ended March 31,
	Notes		2021			2020
Net loss for the period			$	(29,449	)	$	(40,913	)
*Adjustments to reconcile net loss to net cash used in operating activities:*
Depreciation, amortization and accrued contingencies				1,483			1,548
Retirement pension obligations				—			109
Expenses related to share-based payments				1,433			3,073
Other elements				(456	)		419
Changes in operating assets and liabilities:
Decrease (increase) in inventories and work in progress				—			(2,402	)
Decrease (increase) in trade receivables				2,101			—
Decrease (increase) in other current assets				(417	)		122
(Decrease) increase in trade payables				(2,567	)		(3,212	)
(Decrease) increase in other current and non-current liabilities				(7,980	)		(8,382	)
Change in operating lease liabilities and right of use assets				(353	)		(45	)
Net cash flow used in operating activities				(36,204	)		(49,683	)

Cash flows used in investing activities:
Acquisitions of property, plant, and equipment, net from proceeds				(184	)		(816	)
Acquisitions of intangible assets				—			(114	)
Acquisitions of non-current financial assets				(1	)		—

Net cash flows used in investing activities				(185	)		(930	)

Cash flows provided by financing activities:
(Decrease) increase in conditional advances				(164	)		7
Treasury shares				578			(412	)
Capital increases, net of transaction costs				42			151,023
Other cash flows related to financing activities				(17	)		(7	)

Net cash flows provided by financing activities				440			150,611

Effect of exchange rate changes on cash and cash equivalents				(7,944	)		(5,811	)

Net (decrease) / increase in cash and cash equivalents				(43,893	)		94,187

Net Cash and cash equivalents at the beginning of the period				196,352			193,255

Net cash and cash equivalents at the end of the period		3	$	152,459		$	287,442

The accompanying notes are an integral part of these condensed consolidated financial statements.

DBV Technologies S.A.

Condensed Consolidated Statements of Changes in Shareholders’ Equity (unaudited)

(amounts in thousands, except share and per share data)


	Ordinary shares
	Number of Shares		Amount		Additional paid-in capital		Treasury stock			Accumulated deficit			Accumulated other comprehensive income (loss)			Accumulated currency translation effect			Total Shareholders’ Equity
Balance at January 1, 2020		47,028,510	$	5,645	$	1,003,595	$	(230	)	$	(798,988	)	$	108		$	(16,945	)	$	193,186
Net (loss)		—		—		—		—			(40,913	)		—			—			(40,913	)
Other comprehensive income (loss)		—		—		—		—			—			189			(6,064	)		(5,875	)
Issuance of ordinary shares		7,898,677		873		150,150		—			—			—			—			151,023
Treasury shares		—		—		—		(832	)		—			—			—			(832	)
Share-based payments		—		—		3,073					—			—			—			3,073

Balance at March 31, 2020		54,927,187	$	6,518	$	1,156,818	$	(1,062	)	$	(839,901	)	$	297		$	(23,009	)	$	299,662

	Ordinary shares
	Number of Shares		Amount		Additional paid-in capital		Treasury stock			Accumulated deficit			Accumulated other comprehensive gain (loss)			Accumulated currency translation effect			Total Shareholders’ Equity
Balance at January 1, 2021		54,929,187	$	6,518	$	1,152,042	$	(1,169	)	$	(958,543	)	$	484		$	6,158		$	205,491
Net (loss)		—		—		—		—			(29,449	)		—			—			(29,449	)
Other comprehensive (loss)		—		—		—		—			—			(85	)		(8,744	)		(8,829	)
Issuance of ordinary shares		7 500		1		42		—			—			—			—			42
Treasury shares		—		—		—		488			—			—			—			488
Share-based payments		—		—		1,433		—			—			—			—			1,433

Balance at March 31, 2021		54,936,687	$	6,519	$	1,153,516	$	(681	)	$	(987,992	)	$	399		$	(2,586	)	$	169,176

The accompanying notes are an integral part of these condensed consolidated financial statements.

NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED)

Note 1: The Company

Incorporated in 2002 under the laws of France, DBV Technologies S.A. (“DBV Technologies,” or the “Company”, or the “group”) is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin^™. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT^™, a proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin^™.

Basis of Presentation

The condensed consolidated financial statements of the Company and its wholly-owned subsidiaries are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.

The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 17, 2021 (the “Annual Report”). The condensed consolidated statement of financial position at December 31, 2020 was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s critical accounting policies are detailed in the Annual Report. The Company’s critical accounting policies have not changed materially since December 31, 2020.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year ending December 31, 2021, or any other future period.

Use of estimates

The preparation of the Company’s condensed consolidated financial statements requires the use of estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of income and expenses during the period. The Company bases its estimates and assumptions on historical experience and other factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The actual results may differ from these estimates.

On an on-going basis, management evaluates its estimates, primarily those related to: (1) evaluation of costs and measure of progress of the development activities conducted as part of the collaboration agreement with Nestlé Health Science, (2) research tax credits, (3) assumptions used in the valuation of right of use assets - operating lease, (4) impairment of right-of-use assets related to leases and property, plant and equipment, (5) recoverability of the Company’s net deferred tax assets and related valuation allowance, (6) assumptions used in the valuation model to determine the fair value and vesting conditions of share-based compensation plan and, (7) estimate of contingencies.

Going concern

Since its inception, the Company has primarily funded its operations with equity financings, and, to a lesser extent, public assistance aimed at supporting innovation and payments associated with research tax credits (Crédit d’Impôt Recherche). The Company does not generate product revenue and continues to prepare for the potential launch of its first product in the United States and in the European Union, if approved.

Following receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) in connection with its Biologics License Application (“BLA”) for Viaskin^™ Peanut, beginning in August 2020, the Company scaled down its other clinical programs and pre-clinical spend to focus on Viaskin^™ Peanut. The Company also initiated a global restructuring plan in June 2020 to provide operational latitude to progress the clinical development and regulatory review of Viaskin^™ Peanut in the United States and European Union. Based on guidance received from the FDA in January 2021, the Company’s plans to implement such guidance, and expected cost savings from implementation of the global restructuring plan, the Company expects that its current balance of cash and cash equivalents of $152.5 million as of March 31, 2021 will be sufficient to fund its operations for at least the next 12 months.

The Company intends to seek additional capital as it prepares for the launch of Viaskin Peanut, if approved, and continues other research and development efforts. The Company may seek to finance its future cash needs through a combination of public or private equity or debt financings, collaborations, license and development agreements and other forms of non-dilutive financings. As a result of disruptions to the global financial markets as a result of the ongoing COVID-19 pandemic, the Company cannot guarantee that it will be able to obtain the necessary financing to meet its needs or to obtain funds at attractive terms and conditions. The ongoing COVID-19 pandemic has already caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to the Company, including reduced ability to raise additional capital when needed or on acceptable terms, if at all.

Accounting Pronouncements adopted in 2021

Effective January 1, 2021, the Company adopted ASU 2019-12, Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes, which is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. The adoption of ASU 2019-12 did not have a material impact on the Company’s financial position or results of operations.

Accounting Pronouncements issued not yet adopted

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13 - Financial Instruments - Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The FASB has issued ASU 2019-10 which has resulted in the postponement of the effective date of the new guidance for eligible smaller reporting companies to the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. The Company is currently evaluating the impact of the guidance on its Consolidated Financial Statements. The Company does not expect this new standard will have a material impact on its consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, which modifies the goodwill impairment test and requires an entity to write down the carrying value of goodwill for the amount by which the carrying amount of a reporting unit exceeds its fair value. The FASB has issued ASU 2019-10 which has resulted in the postponement of the effective date of the new guidance for eligible smaller reporting companies to the fiscal year beginning January 1, 2023. The Company does not expect this new standard will have a material impact on its consolidated financial statements.

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s Consolidated Financial Statements upon adoption.

Note 2: Significant Events and Transactions

Clinical programs

Viaskin^TM Peanut for children ages 4-11

In January 2020, the Company announced positive topline results of the three-year, open-label extension of its Phase III PEPITES trial, or PEOPLE trial, evaluating the long-term efficacy and safety of investigational Viaskin Peanut in peanut-allergic children ages 4 to 11 years. The results demonstrated long-term clinical benefit as shown by an increase in eliciting dose (“ED”), which may decrease the chance of reacting to an accidental peanut exposure. After three years, the Company observed that 75.9% (107/141) of patients had increased their ED from baseline, and 51.8% (73/141) of patients reached an ED of at least 1,000 mg peanut protein by year three. The safety profile of Viaskin Peanut was consistent with that observed in the clinical program to date in over 1,000 patients. During the PEOPLE trial, the most common adverse events were mild to moderate skin reactions localized to the administration site, and there was no epinephrine use deemed related to treatment. No treatment related serious adverse events were reported. One patient experienced one case of mild anaphylaxis that was determined by the investigator to be possibly related to treatment and resolved without anti-anaphylactic treatment. Treatment compliance remained high throughout the study at a mean of 98% over three years of treatment. Low discontinuations due to adverse events were observed.

In February 2020, the FDA announced an Allergenic Products Advisory Committee meeting to be held on May 15, 2020 to discuss the Biologics License Application (BLA) for Viaskin Peanut. On March 16, 2020, the Company announced that the FDA had informed us that during its ongoing review of the Company’s BLA for Viaskin Peanut, it had identified questions regarding efficacy, including the impact of patch-site adhesion. Therefore, the Advisory Committee meeting to discuss the BLA originally scheduled on May 15, 2020 was cancelled.

On August 4, 2020, the Company announced that FDA has issued a Complete Response Letter in which the FDA indicated it could not approve the Viaskin Peanut BLA in its current form. The FDA identified concerns regarding the impact of patch-site adhesion on efficacy and indicated the need for patch modifications, and subsequently a new human factor study. The FDA also indicated that supplementary clinical data would need to be generated to support the modified patch. In addition, the FDA requested additional Chemistry, Manufacturing and Controls, or CMC, data. The FDA did not raise any safety concerns related to Viaskin Peanut.

requested an assessment comparing the uptake of allergen (peanut protein) between the patches in peanut allergic children ages 4 to 11 years. The FDA also recommended conducting a 6-month, well-controlled safety and adhesion trial to assess the modified Viaskin Peanut patch in the intended patient population.

On November 2, 2020, the Company announced that its Marketing Authorization Application, or MAA, for Viaskin Peanut had been validated by the European Medicines Agency, or EMA. The validation of the MAA confirmed that the submission was sufficiently complete to begin the formal review process for Viaskin Peanut to treat peanut allergies in children ages 4 to 11 years. The Company received the first set of questions from the EMA, during the first quarter of 2021, which were consistent with the Company’s expectations and prefiling conversations with the EMA. The Company did not receive questions about the impact of adhesion on efficacy. The EMA’s Committee for Medicinal Products for Human Use will provide a recommendation to the European Commission, or EC, on whether to grant a marketing authorization when its review of the Viaskin Peanut MAA is complete.

Viaskin Peanut for children ages 1-3

On June 26, 2020, the Company announced that in Part A, patients in both treatment arms showed consistent treatment effects after 12 months of therapy, as assessed by a double-blind placebo-controlled food challenge and biomarker results. Part A subjects were not included in Part B and the efficacy analyses from Part A were not statistically powered to demonstrate superiority of either dose versus placebo. These results validate the ongoing investigation of the 250 mg dose in this age group, which is the dose being studied in Part B of the study. Enrollment for Part B of EPITOPE was completed in the first quarter of 2021.

Financing

On February 4, 2020, the Company announced the closing of an underwritten global offering of an aggregate of 7,500,000 ordinary shares in (i) a public offering of 4,535,581 ordinary shares in the form of 9,071,162 American Depositary Shares (“ADSs”) in the United States, Canada and certain countries outside Europe at a public offering price of $10.25 per ADS (on the basis of an exchange rate of $1.0999 = €1.00), and (ii) an offering exclusively addressed to qualified investors in Europe (including France) of 2,964,419 ordinary shares at an offering price of €18.63 per ordinary share (together, the “Global Offering”).

On March 2, 2020, the Company announced that the underwriters partially exercised their option to purchase 338,687 additional ordinary shares in the form of 677,374 ADSs at an offering price of $10.25 per ADS, before deducting commissions and estimated offering expenses (the “Option”). The Option closed on March 4, 2020.

Consequently, following partial exercise of the Option, the total number of ordinary shares sold in the global offering was 7,838,687 ordinary shares, including 4,874,268 ordinary shares in the form of 9,748,536 ADSs, bringing the total gross proceeds from the global offering to $160.7 million and net proceeds of $150.0 million.

Restructuring

The Company initiated a global restructuring plan in June 2020 to provide operational latitude to progress in the clinical development and regulatory review of investigational Viaskin Peanut in the United States and European Union. The Company expects full implementation of the organization-wide costs reduction measures to be completed by the second half of 2021.

The following table summarizes restructuring activities as of March 31, 2021 included in current contingencies and other current liabilities in the statement of financial position:


	Restructuring liabilities
Restructuring liability - January 1, 2021		9,387
Amounts paid		(4,854	)
Other effect including currency translation effect		(220	)

Restructuring liability - March 31, 2021		4,313

of which current contingencies		1,511
of which other current liabilities		2,803

COVID-19 Pandemic

On March 11, 2020, the World Health Organization declared COVID-19 a pandemic. This global health crisis led many countries to impose national containment measures and travel bans. In view of this exceptional situation, the Company decided to take all measures

aimed primarily at guaranteeing the safety of its employees and the continuation of ongoing clinical trials, in compliance with the directives of the authorities in each country. The Company has experienced a decrease in new patients enrolling in the ongoing clinical studies and it has had to adapt the protocols of its clinical trials because patients remain subject to travel restrictions.

The Company has assessed the impact of the uncertainties created by the pandemic. As of March 31, 2021, those uncertainties were taken into account in the assumptions underlying the estimates and judgments used by the Company. The Company continues to update these estimates and assumptions as the situation evolves. The effects of the COVID-19 pandemic are presented in the relevant line items of the condensed consolidated statement of financial position and the condensed consolidated statement of operations according to the function or nature of the income or expense.

Legal Proceedings

A class action complaint was filed on January 15, 2019 in the United States District Court for the District of New Jersey, entitled Travis Ito-Stone v. DBV Technologies, et al., Case No. 2:19-cv-00525. The complaint alleged that the Company and its former Chief Executive Officer, its current Chief Executive Officer, and its former Deputy Chief Executive Officer violated certain federal securities laws, specifically under Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5 promulgated thereunder. The plaintiffs seek unspecified damages on behalf of a purported class of purchasers of the Company’s securities between February 14, 2018 and March 16, 2020.

The Company believes that the allegations contained in the amended complaint are without merit and will defend the case vigorously. The Company believes this complaint will not have a material adverse effect on the Company’s consolidated financial position, results of operations or liquidity.

Note 3: Cash and Cash Equivalents

The following table presents for each reported period, the breakdown of cash and cash equivalents:


	March 31,		December 31,
	2021		2020
Cash		58,069		42,341
Cash equivalents		94,390		154,011

Total cash and cash equivalents as reported in the statements of financial position		152,459		196,352

Cash equivalents are immediately convertible into cash at no or insignificant cost, on demand. They are measured using level 1 fair value measurements.

Note 4: Trade Payables and Other Current Liabilities

4.1 Trade Payables

No discounting was performed on the trade payables to the extent that the amounts did not present payment terms longer than one year at the end of each fiscal period presented.

4.2 Other Current Liabilities

Other current liabilities consisted of the following:


	March 31,		December 31,
	2021		2020
Employee related liabilities		9,245		16,661
Deferred income		3,378		4,687
Tax liabilities		312		580
Other debts		460		999

Total		13,394		22,926

The other current liabilities include short-term debt to employees including employee termination allowance and benefits as part of the restructuring (refer to Note 2, “Significant Events and Transactions of the Period – Restructuring”), bonus accruals, and social welfare and tax agency obligations.

Deferred income primarily includes deferred income from the collaboration agreement with Nestlé Health Science, which amounted to $3.4 million as of March 31, 2021.

Note 5: Share-Based Payments

The Board of Directors has been authorized by the General Meeting of the Shareholders to grant restricted stock units (“RSU”), stock options plan (“SO”), employee warrants (Bons de Souscription de Parts de Créateur d’Entreprise or “BSPCE”) and (Bons de Souscription d’Actions or “BSA”).

During the three months ended March 31, 2021, the Company granted 75,600 stock options and 24,900 restricted stock.

There have been no changes in the vesting conditions and method of valuation of the SO and RSUs from that disclosed in Note 14 to the consolidated financial statements included in the Annual Report.


Stock options fair value assumptions during the three months ended March 31, 2021
Weighted average share price at grant date in €	9.3
Weighted average expected volatility	90.9	%
Weighted average risk-free interest rate	(0.36	)%
Weighted average expected term (in years)	6
Dividend yield	—
Weighted average fair value of stock-options in €	6.9

Change in Number of BSA/BCE/SO/RSU


	Number of outstanding
	BSA		BCE			SO			RSUs
Balance as of December 31, 2020		218,008		5,500			2,610,510			1,118,745
Granted during the period		—		—			75,600			24,900
Forfeited during the period		—		—			(15,400	)		(13,700	)
Exercised/released during the period		—		(500	)		—			—
Expired during the period		—		—			—			—

Balance as of March 31, 2021		218,008		5 000			2,670,710			1,129,945

Reconciliation of the share-based payments expenses with the consolidated statements of operations


	Three Months Ended March 31,
	2021				2020
Research and development		SO	(376	)		(876	)
		RSU	(251	)		(392	)
Sales and marketing		SO	(49	)		(598	)
		RSU	(22	)		(2	)
General and administrative		SO	(644	)		(1,071	)
		RSU	(91	)		(133	)

Total share-based compensation expense			(1,433	)		(3,073	)

Note 6: Contingencies

Current contingencies and non-current contingencies break down as follows:


	March 31,		December 31,
	2021		2020
Current contingencies		4,246		5,016
Non-current contingencies		2,229		2,527

Total contingencies		6,474		7,542

The table below shows movements in contingencies:


	Pension retirement obligations			Collaboration agreement - Loss at completion			Other contingencies			Total
At January 1, 2021		937			3,956			2,649			7,542
Increases in liabilities		—			—			—			—
Used liabilities		—			(434	)		(515	)		(949	)
Reversals of unused liabilities		—			—			—			—

Net interest related to employee benefits, and unwinding of discount		—			—			—			—
Actuarial gains and losses on defined-benefit plans		85			—			—			85
Other effects including currency translation effect		(44	)		(164	)		4			(204	)

At March 31, 2021		978			3,358			2,139			6,474

Of which current		—			2,107			2,139			4,246
Of which non-current		978			1,251			—			2,229

In 2020 and during the first three months of 2021, the ongoing COVID-19 pandemic impacted the Company’s current clinical trials, including its Phase II clinical trial conducted as part of the development activities pursuant to the collaboration and license agreement with Nestlé Health Science. The Company experienced a decrease in new patients enrolling in this Phase II clinical trial and modified the protocols of the clinical trial. As a result of these delays, the Company expects to incur additional clinical and production costs related to the Phase II clinical trial. Starting the last quarter of the fiscal year 2020, an accrual in the amount of the difference between the Company’s current best estimates of costs yet to be incurred and revenues yet to be recognized for the completion of the Phase II clinical trial has been recorded.

Other contingencies are primarily composed of the estimated expenses to be incurred as part of the employee-related costs related to restructuring, as well as estimated cost of refurbishing lease premises (Refer to Note 2, “Significant Events and Transactions—Restructuring contingencies).

There have been no significant changes in assumptions for the estimation of the retirement commitments from those disclosed in Note 15 to the consolidated financial statements included in the Annual Report.

Note 7: Operating income

The operating income is broken down in the following manner:


	Three Months Ended March 31,
	2021		2020
Research tax credit		1,807		2,902
Other operating income		1,133		1,818

Total		2,941		4,720

As of March 31, 2021, the Company recorded its collaboration contract’s income based on its updated measurement of progress of the Phase II clinical trial conducted as part of the collaboration and license agreement with Nestlé Health Science. The accrual recorded in the amount of the difference between the Company’s current best estimates of costs yet to be incurred and income yet to be recognized for the completion of the Phase II clinical trial has been updated accordingly.

Note 8: Allocation of Personnel Expenses

The Company had an average of 121 employees during the three months ended March 31, 2021, in comparison with an average of 311 employees during the three months ended March 31, 2020.

Allocation of Personnel Expenses by Function:


	Three Months Ended March 31,
	2021		2020
Research and development expenses		4,718		10,204
Sales and marketing expenses		518		4,197
General and administrative expenses		3,766		4,283

Total personnel expenses		9,002		18,684

Allocation of Personnel Expenses by Nature:


	Three months Ended March 31,
	2021		2020
Wages and salaries		4,454		12,872
Social security contributions		1,332		663
Expenses for pension commitments		402		915
Employer contribution to bonus shares		1,381		1,162
Share-based payments		1,433		3,073

Total personnel expenses		9,002		18,684

The decrease in personnel expenses is mainly due to a decreased headcount as well as reductions in accrued bonuses, retention measures and share-based compensation expenses, partly as a result of the 2020 global restructuring plan.

Note 9: Commitments

There have been no significant changes in other commitments from those disclosed in Note 19 to the consolidated financial statements included in the Annual Report.

Note 10: Relationships with Related Parties

There were no new significant related-party transactions during the period nor any change in the nature of the transactions from those described in Note 20 to the consolidated financial statements included in the Annual Report.

Note 11: Loss Per Share

Basic loss per share is calculated by dividing the net loss attributable to the shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. As the Company was in a loss position for each of the three months ended March 31, 2021 and 2020, the diluted loss per share is equal to basic loss per share because the effects of potentially dilutive shares were anti-dilutive as a result of the Company’s net loss.

The following is a summary of the ordinary share equivalents that were excluded from the calculation of diluted net loss per share for each of the three months ended March 31, 2021 and 2020 indicated in number of potential shares:


	Three Months Ended March 31,
	2021		2020
Non-employee warrants		225,008		225,008
Employee warrants		75,000		82,500
Stock-options		2,670,710		2 835,635
Restricted stock units		1,129,945		696,895

Note 12: Events after the Close of the Period

The Company evaluated subsequent events that occurred after March 31, 2021, through the date the condensed consolidated financial statements were issued after their approval by the Board of Directors on April 30, 2021 and determined that there are no significant events that require adjustments or disclosure in such condensed consolidated financial statements.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part 1, Item 1 of this Report and with our audited financial statements and related notes thereto for the year ended December 31, 2020, included in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 17, 2021, or the Annual Report. This discussion and other parts of this Report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause such differences are discussed in the section of this Report titled “Special Note Regarding Forward-Looking Statements” and under “Item 1A. Risk Factors” in the Annual Report.

Overview

We are a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT^TM, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. We have generated significant data demonstrating that Viaskin’s mechanism of action is novel and differentiated, as it targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. We are advancing this unique technology to treat patients, including infants and children, suffering from food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock.

On January 13, 2021, the Company received written responses from the FDA to questions provided in the Type A meeting request the Company submitted in October 2020 following the CRL. We believe the FDA feedback provides a well-defined regulatory path forward. In exchanges with the FDA, we proposed potential resolutions to two main concerns identified by the FDA in the CRL: the impact of patch adhesion and the need for patch modifications. The FDA agreed with our position that a modified Viaskin Peanut patch should not be considered as a new product entity provided the occlusion chamber of the current Viaskin Peanut patch and the peanut protein dose of 250 µg (approximately 1/1000 of a peanut) remains unchanged and performs in the same way it has performed previously. In order to confirm the consistency of efficacy data between the existing and modified patches, the FDA has requested an assessment comparing the uptake of allergen (peanut protein) between the patches in peanut allergic children ages 4 to 11 years. The FDA also recommended conducting a 6-month, well-controlled safety and adhesion trial to assess the modified Viaskin Peanut patch in the intended patient population. We intend to submit the protocols for the safety and adhesion study and the allergen uptake study to the FDA for review and comments before initiating the trials. We will address details about a new human factor, or HF, validation study and additional CMC data in subsequent interactions with the FDA

During the first quarter of 2021, we received the first set of questions from the European Medicines Agency, or EMA, regarding the Marketing Authorization Application, or MAA, for Viaskin Peanut as a treatment for peanut allergy in children ages 4-11.. The questions were consistent with our expectations and prefiling conversations with the EMA. We did not receive questions about the impact of adhesion on efficacy. The EMA’s Committee for Medicinal Products for Human Use will provide a recommendation to the European Commission, or EC, on whether to grant a marketing authorization when its review of the Viaskin Peanut MAA is complete.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the revenue, costs and expenses recognized during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no new policies or significant changes to our critical accounting policies as disclosed in the critical accounting policies described in the Annual Report. Our significant accounting policies are more fully described in Note 1 of the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Report.

The following table summarizes our results of operations, derived from our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP and presented in thousands of U.S. Dollars for the three months ended March 31, 2021 and 2020:


	Three Months Ended March 31,
	2021			2020
Operating income	$	2,941		$	4,720

Operating expenses
Research and development expenses		(22,164	)		(27,532	)
Sales and marketing expenses		(729	)		(7,297	)
General and administrative expenses		(9,683	)		(11,113	)
Restructuring expenses		—			—

Total Operating expenses		(32,575	)		(45,942	)

Financial income		215			309

Income tax		(30	)		—

Net loss	$	(29,449	)	$	(40,913	)

Basic/diluted Net loss per share attributable to shareholders	$	(0.54	)	$	(0.79	)

Comparison of the three months ended March 31, 2021 to the three months ended March 31, 2020

Operating Income

We generated operating income of $2.9 million during the three months ended March 31, 2021 compared to $4.7 million during the three months ended March 31, 2020, a decrease of 37.7%. This income was mainly generated from the French research tax credit (crédit d’impôt recherche), or CIR, and by revenue recognized under our collaboration agreement with Nestlé Health Science.

Three Months Ended March 31

% change

2021

2020

2021 vs 2020

Sales

—

Other income

2,941

4,720

(37.7

Research tax credit

1,807

2,902

(37.7

Other operating income

1,133

1,818

(37.6

Total operating income

2,941

4,720

(37.7

The decrease in operating income is primarily attributable to the decrease of the CIR, as eligible expenses have declined in correlation with Research and Development costs.

As of March 31, 2021, we recorded our collaboration contract income based on our updated measurement of progress of the Phase II clinical trial conducted as part of the collaboration and license agreement with Nestlé Health Science. The accrual recorded in the amount of the difference between our current best estimates of costs yet to be incurred and income yet to be recognized for the completion of the Phase II clinical has been updated accordingly.

Operating Expense

The following table summarizes our operating expense excluding restructuring incurred during the three months ended March 31, 2021 and 2020:


	Three months Ended March 31				% change
	2021		2020		2021 vs 2020
Research and development expenses		22,164		27,532		(19.5	)%
Sales and marketing expenses		729		7,297		(90.0	)%
General and administrative expenses		9,683		11,113		(12.9	)%

Total operating expenses		32,575		45,942		(29.1	)%

Operating expenses for the three months ended March 31, 2021 were $32.6 million compared to $45.9 million for the three months ended March 31, 2020. The $13.4 million decrease in operating expenses is mainly attributable to a decrease in personnel expenses directly related to the workforce reduction we implemented as part of our 2020 global restructuring plan. Personnel expenses decreased by $9.7 million, or 52%, to $9.0 million during the three months ended March 31, 2021 from $18.7 million for the three months ended March 31, 2020. Average headcount decreased 61% between the two periods, from 311 FTEs for the three months ended March 31, 2020 to and 121 FTEs for the three months ended March 31, 2021. By function, the personnel expenses, including share-based payment expenses, decreased as follows:


	Three Months Ended March 31,				% change
	2021		2020		2021 vs 2020
Research and development expenses		4,718		10,204		(53.8	)%
Sales and marketing expenses		518		4,197		(87.7	)%
General and administrative expenses		3,766		4,283		(12.1	)%

Total personnel expenses		9,002		18,684		(51.8	)%

The decrease in other operating expenses was primarily due to the budget discipline measures taken by DBV. In particular, sales and marketing consulting fees dropped by 96.8% or $2.6 million, from $2.7 million for the three months ended March 31, 2020 to $0.1 million for the three months ended March 31, 2021 and general and administrative fees decreased by 43.5% or $1.7 million, from $4.0 million for the three months ended March 31, 2020 to $2.3 million for the three months ended March 31, 2021.

As a result of the ongoing COVID-19 pandemic, we also experienced a decrease in other expenses, in particular tradeshows and travel expenses.

Restructuring

We initiated a global restructuring plan in June 2020 to provide operational latitude to progress in the clinical development and regulatory review of investigational Viaskin^™ Peanut in the United States and European Union.

We expect full implementation of the restructuring plan to result in a reduction of more than 200 jobs, resulting in a remaining global team of 90 individuals dedicated to the pursuit of innovation and scientific development of novel therapies.

As of March 31, 2021, we had 104 employees. We expect full implementation of the organization-wide costs reduction measures to be completed by the second half of 2021.

The restructuring costs, which were $23.6 million as of December 31, 2020, were mainly comprised of payroll expenses, restructuring-related consulting and legal fees, as well as impairment of facilities and right of use assets following resizing of facilities.

During the three months ended March 31, 2021, the restructuring liability evolved as presented below:


	Restructuring liabilities
Restructuring liability - January 1, 2021		9,387
Amounts paid		(4,854	)
Other effect including currency translation effect		(220	)

Restructuring liability - March 31, 2021		4,313

of which current contingencies		1,511
of which other current liabilities		2,803

They were no restructuring costs for three months ended March 31, 2021 and 2020.

Financial income

Our financial income was $0.2 million for the three months ended March 31, 2021 and 2020. This item mainly includes foreign exchange income.

Net loss

Net loss was $29.4 million for the three months ended March 31, 2021, compared to $40.9 million for the three months ended March 31, 2020. Net loss per share (based on the weighted average number of shares outstanding over the period) was $0.54 and $0.79 for three months ended March 31, 2021 and 2020, respectively.

Summary Statement of Cash Flows

The table below summarizes our sources and uses of cash for the three months ended March 21, 2021 and 2020.


	Three Months Ended March 31,						% change
(Amounts in thousands of U.S. Dollars)	2021			2020			2021 vs 2020
Net cash flow used in operating activities		(36,204	)		(49,683	)		(27.1	)%
Net cash flow used in investing activities		(185	)		(930	)		(80.1	)%
Net cash flow provided by financing activities		440			150,611			(99.7	)%
Effect of exchange rate changes on cash and cash equivalents		(7,944	)		(5,811	)		(36.7	)%

Net (decrease) increase in cash and cash equivalents		(43,893	)		94,187			(146.6	)%

Operating Activities

Our net cash flows used in operating activities were $36.2 million and $49.7 million during the three months ended March 31, 2021 and 2020, respectively. Our net cash flows used in operating activities decreased by $13.5 million, or 27.2%, mainly due to the budget discipline measures we took, in particular the decrease in personnel expenses, which was directly related to the workforce reduction we implemented as part of our global restructuring plan. Cash flows used in operating activities for the three months ended March 31, 2021 included $4.9 million in restructuring amounts paid.

Investing Activities

Our net cash flows used in investing activities were $0.2 million and $0.9 million during the three months ended March 21, 2021 and 2020, respectively. Those investments were mainly for our industrial machinery and equipment, which are commissioned in order to support the commercialization of Viaskin Peanut, if approved.

Financing Activities

Our net cash flows provided by financing activities decreased to $0.4 million during the three months ended March 21, 2021 from $150.6 million during the three months ended March 21, 2020. Financing activities consisted mainly of our underwritten global offering in the first quarter of 2020.

Based on our current assumptions, we expect that our current cash and cash equivalents will support our operations until the second half of 2022

Contractual Obligations and Other Commitments

There have been no material changes in our contractual obligations and commitments from those disclosed in the Annual Report.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements and do not have variable interests in variable interest entities.

Smaller Reporting Company Status

We are a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended. We may, and intend to, take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as we are a smaller reporting company. We may be a smaller reporting company in any year in which (i) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) (a) our annual revenue is less than $100.0 million during the most recently completed fiscal year and (b) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Our market risks have not changed materially from those disclosed in Item 7A of the Annual Report.

Item 4.

Controls and Procedures

Disclosure Controls and Procedures

Based on their evaluation as of March 31, 2021, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) were effective to provide reasonable assurance that (i) the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitation on Effectiveness of Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and

procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error of fraud may occur and not be detected.

PART II – Other information

Item 1.

Legal Proceedings

See “Note 2: Significant Events and Transactions – Legal Proceedings” in the notes to the condensed consolidated financial statements included elsewhere in this Report.

Item 1A.

Risk Factors

There have been no material changes in our risk factors from those disclosed in the Annual Report.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended March 31, 2021, we granted 75,600 stock options and 24,900 restricted stock units to employees in France and in the United States.

During the three months ended March 31, 2021, we issued 7,500 ordinary shares following the exercise of employee warrants by an employee in France, for proceeds of $42,000.

None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe these transactions were exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act or Regulation S promulgated under Section 5 of the Securities Act, as transactions by an issuer not involving any public offering or as offerings made to non-U.S. resident employees pursuant to an employee benefit plan established and administered in accordance with the law of a country other than the United States (namely, the Republic of France) and in accordance with that country’s practices and documentation. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

Not applicable.

Item 6. Exhibits.

Exhibit Index

Exhibit

Description

Incorporated by Reference

Schedule
/ Form

File
Number

Exhibit

File
Date

3.1

By-laws (statuts) of the registrant (English translation)

10-K

001-36697

3.1

3/17/2021

31.1

Certificate of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as Amended

31.2

Certificate of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended

32.1*

Certificate of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002, as amended

101.INS

XBRL Instance Document

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

XBRL Taxonomy Extension Labels Linkbase Document

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Exchange Act, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	DBV Technologies S.A.

Date: May 5, 2021
	By:	/s/ Daniel Tassé
	Daniel Tassé
	Chief Executive Officer)
	(Principal Executive Officer)

Date: May 5, 2021	By:	/s/ Sébastien Robitaille
	Sébastien Robitaille
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-31.1 2 d172290dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

I, Daniel Tassé, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of DBV Technologies S.A.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 3 d172290dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION

I, Sébastien Robitaille, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of DBV Technologies S.A.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32.1 4 d172290dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Daniel Tassé, Chief Executive Officer of DBV Technologies S.A. (the “Company”), and Sébastien Robitaille, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1.	The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2021, to which this Certification is attached as Exhibit 32.1 (the “Quarterly Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and

2.	The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 5, 2021

IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 5th day of May, 2021.


By:	/s/ Daniel Tasse	By:	/s/ Sébastien Robitaille
	Daniel Tasse		Sébastien Robitaille
	Chief Executive Officer		Chief Financial Officer
	(Principal Executive Officer)		(Principal Financial and Accounting Officer)

This certification accompanies the Quarterly Report, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Quarterly Report), irrespective of any general incorporation language contained in such filing.

EX-101.INS 5 dbvt-20210331.xml XBRL INSTANCE DOCUMENT 0001613780 2021-03-31 0001613780 2020-12-31 0001613780 2021-01-01 2021-03-31 0001613780 2020-01-01 2020-03-31 0001613780 2021-04-30 0001613780 2020-02-04 2020-02-04 0001613780 2019-12-31 0001613780 2020-03-31 0001613780 us-gaap:CommonStockMember 2020-12-31 0001613780 dbvt:EmployeeRelatedLiabilitiesMember 2020-12-31 0001613780 dbvt:DeferredIncomeMember 2020-12-31 0001613780 dbvt:TaxLiabilitiesMember 2020-12-31 0001613780 dbvt:OtherDebtsMember 2020-12-31 0001613780 us-gaap:CommonStockMember 2021-03-31 0001613780 dbvt:EmployeeRelatedLiabilitiesMember 2021-03-31 0001613780 dbvt:DeferredIncomeMember 2021-03-31 0001613780 dbvt:TaxLiabilitiesMember 2021-03-31 0001613780 dbvt:OtherDebtsMember 2021-03-31 0001613780 dbvt:NestlHealthScienceMember 2021-03-31 0001613780 dbvt:OtherProvisionsInclRestructuringMember 2021-03-31 0001613780 dbvt:CollaborationAgreementLossAtCompletionMember 2021-03-31 0001613780 us-gaap:PostemploymentRetirementBenefitsMember 2021-03-31 0001613780 dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2021-03-31 0001613780 srt:WeightedAverageMember 2021-03-31 0001613780 dbvt:ExpensesByFunctionMember 2020-01-01 2020-03-31 0001613780 dbvt:ExpensesByNatureMember 2020-01-01 2020-03-31 0001613780 dbvt:NonemployeewarrantsMember 2020-01-01 2020-03-31 0001613780 dbvt:EmployeewarrantsMember 2020-01-01 2020-03-31 0001613780 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001613780 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0001613780 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001613780 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001613780 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001613780 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001613780 us-gaap:SellingAndMarketingExpenseMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001613780 us-gaap:SellingAndMarketingExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001613780 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001613780 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001613780 dbvt:ExpensesByFunctionMember 2021-01-01 2021-03-31 0001613780 dbvt:ExpensesByNatureMember 2021-01-01 2021-03-31 0001613780 dbvt:NonemployeewarrantsMember 2021-01-01 2021-03-31 0001613780 dbvt:EmployeewarrantsMember 2021-01-01 2021-03-31 0001613780 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001613780 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0001613780 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001613780 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001613780 dbvt:OtherProvisionsInclRestructuringMember 2021-01-01 2021-03-31 0001613780 dbvt:CollaborationAgreementLossAtCompletionMember 2021-01-01 2021-03-31 0001613780 us-gaap:PostemploymentRetirementBenefitsMember 2021-01-01 2021-03-31 0001613780 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001613780 us-gaap:CommonStockMember dbvt:PublicOfferingMember 2021-01-01 2021-03-31 0001613780 dbvt:AmericanDepositarySharesMember dbvt:PublicOfferingMember 2021-01-01 2021-03-31 0001613780 srt:WeightedAverageMember 2021-01-01 2021-03-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001613780 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001613780 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001613780 us-gaap:SellingAndMarketingExpenseMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001613780 us-gaap:SellingAndMarketingExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001613780 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001613780 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001613780 dei:AdrMember 2021-01-01 2021-03-31 0001613780 dbvt:GlobalOfferingMember 2021-01-01 2021-03-31 0001613780 dbvt:BCEWarrantsMember 2021-01-01 2021-03-31 0001613780 dbvt:BSAWarrantsMember 2021-01-01 2021-03-31 0001613780 dbvt:EmployeesMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001613780 dbvt:EmployeesMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001613780 dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember srt:MinimumMember 2020-01-31 2020-01-31 0001613780 dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember srt:MaximumMember 2020-01-31 2020-01-31 0001613780 dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2020-01-31 2020-01-31 0001613780 dbvt:ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember 2020-01-31 0001613780 dbvt:PublicOfferingMember us-gaap:CommonStockMember 2020-02-04 2020-02-04 0001613780 dbvt:PublicOfferingMember us-gaap:CommonStockMember dbvt:OutsideEuropeMember 2020-02-04 2020-02-04 0001613780 dbvt:PublicOfferingMember dbvt:AmericanDepositarySharesMember dbvt:OutsideEuropeMember 2020-02-04 2020-02-04 0001613780 us-gaap:PrivatePlacementMember 2020-02-04 2020-02-04 0001613780 dbvt:PublicOfferingMember dbvt:OutsideEuropeMember dbvt:AmericanDepositarySharesMember 2020-02-04 0001613780 us-gaap:PrivatePlacementMember 2020-02-04 0001613780 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2020-03-02 2020-03-02 0001613780 dbvt:AmericanDepositarySharesMember us-gaap:OverAllotmentOptionMember 2020-03-02 2020-03-02 0001613780 dbvt:AmericanDepositarySharesMember us-gaap:OverAllotmentOptionMember 2020-03-02 0001613780 us-gaap:CommonStockMember 2019-12-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001613780 us-gaap:TreasuryStockMember 2019-12-31 0001613780 us-gaap:RetainedEarningsMember 2019-12-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001613780 us-gaap:CommonStockMember 2020-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001613780 us-gaap:TreasuryStockMember 2020-03-31 0001613780 us-gaap:RetainedEarningsMember 2020-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001613780 us-gaap:TreasuryStockMember 2020-12-31 0001613780 us-gaap:RetainedEarningsMember 2020-12-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0001613780 us-gaap:PostemploymentRetirementBenefitsMember 2020-12-31 0001613780 dbvt:OtherProvisionsInclRestructuringMember 2020-12-31 0001613780 dbvt:CollaborationAgreementLossAtCompletionMember 2020-12-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001613780 us-gaap:RestrictedStockUnitsRSUMember 2021-03-31 0001613780 us-gaap:TreasuryStockMember 2021-03-31 0001613780 us-gaap:RetainedEarningsMember 2021-03-31 0001613780 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001613780 us-gaap:AccumulatedTranslationAdjustmentMember 2021-03-31 0001613780 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001613780 dbvt:BSAWarrantsMember 2020-12-31 0001613780 dbvt:BCEWarrantsMember 2020-12-31 0001613780 dbvt:BSAWarrantsMember 2021-03-31 0001613780 dbvt:BCEWarrantsMember 2021-03-31

152459000

196352000

2230000

7349000

8792000

159809000

207375000

21526000

24792000

9168000

10104000

32000

41000

30870000

29935000

61596000

64871000

221405000

272246000

17176000

20338000

3314000

3708000

701000 724000 4246000 5016000

13394000

22926000

38831000

52713000

9533000

10496000

350000 543000 2229000 2527000

1286000

475000

13398000

14042000

6519000

6518000

1153516000

1152042000

681000

1169000

-987992000

-958543000

399000

484000

-2586000 6158000

169176000

205491000

221405000

272246000

0.10

54936687

54929187

54936687

4100663

4029763

2941000

4720000

22164000

27532000

729000

7297000

9683000

11113000

32575000

45942000

-29634000

-41222000

215000 309000

-29419000

-40913000

30000

-29449000

-40913000

-0.54

-0.79

109000

1433000

3073000

456000

-419000

2402000

-2101000

417000

-122000

-2567000

-3212000

-7980000

-8382000

353000 45000

-36204000

-49683000

184000

816000

114000

1000

-185000

-930000

-164000

7000

578000 -412000

-17000

-7000

440000

150611000

-43893000

94187000

193255000

-7944000

-5811000

287442000

4718000

10204000

518000

4197000

3766000

4283000

9002000

18684000

4454000 12872000 1332000 663000 402000 915000

1433000

3073000

9002000

18684000

1381000 1162000

58069000

42341000

94390000 154011000 10-Q false 2021-03-31 2021 Q1 DBV Technologies S.A. 0001613780 --12-31 Non-accelerated Filer Yes false false FR Yes false

225008000

75000000

82500000

2670710000

2835635000

1129945000

696895000

1807000 2902000 1133000 1818000

9245000

16661000

3378000

4687000

312000

580000

460000

999000

5645000

1003595000

-230000

-798988000

108000

-16945000

193186000

6518000

1152042000

-1169000

-958543000

484000

6158000

3400000

-40913000

-29449000

189000

-6064000

-5875000

-85000

-8744000

-8829000

873000

150150000

151023000

1000

42000

3073000

1433000

6518000

1156818000

-1062000

-839901000

297000

-23009000

299662000

6519000

-681000

-987992000

399000

-2586000

1153516000

47028510

54929187

54927187

54936687

4246000

5016000

2229000

2527000

6474000

7542000

937000

2649000

7542000

3956000

515000

949000

434000

85000

-44000

4000

-204000

-164000

978000

3358000

2139000

6474000

2139000

2107000

978000

1251000

0.759 107 141 0.518 0.73 1000 0.98 P6M

7500000

4535581

9071162

338687

677374

7838687

4874268

9748536

10.25

18.63

10.25

P4Y P11Y

150000000

160700000

9387000

4854000

4313000

1511000

2803000

9.3

0.909

0.0036

P6Y

1118745

24900

13700

1129945

-376000

-876000

-251000

-392000

-49000

-598000

-22000

-2000

-644000

-1071000

-91000

-133000

-1433000

-3073000

true American Depositary Shares, each representing one-half of one ordinary share, nominal value €0.10 per share Ordinary shares, nominal value €0.10 per share true dbvt NYSE NYSE I0

7898677

7500

-832000

488000

2941000 4720000

42000

151023000

52229000

66754000

54880776

51802524

1483000 1548000

2964419

1.0999

60588

112302

6.9

true

220000

218008

5500

218008

-500 0

2610510

2670710

75600

15400

75600

24900

0 54936687

-8744000

-6064000

-85000

189000

-38279000

-46788000

<div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 1: The Company </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Incorporated in 2002 under the laws of France, DBV Technologies S.A. (“DBV Technologies,” or the “Company”, or the “group”) is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin<div style="font-size: 85%; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">™</div>. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT<div style="font-size: 85%; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">™</div>, a proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin<div style="font-size: 85%; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">™</div>. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of Presentation </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The condensed consolidated financial statements of the Company and its wholly-owned subsidiaries are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed with the SEC on March 17, 2021 (the “Annual Report”). The condensed consolidated statement of financial position at December 31, 2020 was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s critical accounting policies are detailed in the Annual Report. The Company’s critical accounting policies have not changed materially since December 31, 2020. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year ending December 31, 2021, or any other future period. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of estimates </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the Company’s condensed consolidated financial statements requires the use of estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of income and expenses during the period. The Company bases its estimates and assumptions on historical experience and other factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The actual results may differ from these estimates. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">On an <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> basis, management evaluates its estimates, primarily those related to: (1) evaluation of costs and measure of progress of the development activities conducted as part of the collaboration agreement with Nestlé Health Science, (2) research tax credits, (3) assumptions used in the valuation of right of use assets - operating lease, (4) impairment of <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets related to leases and property, plant and equipment, (5) recoverability of the Company’s net deferred tax assets and related valuation allowance, (6) assumptions used in the valuation model to determine the fair value and vesting conditions of share-based compensation plan and, (7) estimate of contingencies. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Going concern </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Since its inception, the Company has primarily funded its operations with equity financings, and, to a lesser extent, public assistance aimed at supporting innovation and payments associated with research tax credits (<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cr</div><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">é</div><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">dit d</div><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">’</div><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Imp</div><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">ô</div><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">t Recherche</div>). The Company does not generate product revenue and continues to prepare for the potential launch of its first product in the United States and in the European Union, if approved. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) in connection with its Biologics License Application (“BLA”) for Viaskin<div style="font-size: 85%; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">™</div> Peanut, beginning in August 2020, the Company scaled down its other clinical programs and <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> spend to focus on Viaskin<div style="font-size: 85%; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">™</div> Peanut. The Company also initiated a global restructuring plan in June 2020 to provide operational latitude to progress the clinical development and regulatory review of Viaskin<div style="font-size: 85%; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">™</div> Peanut in the United States and European Union. Based on guidance received from the FDA in January 2021, the Company’s plans to implement such guidance, and expected cost savings from implementation of the global restructuring plan, the Company expects that its current balance of cash and cash equivalents of $152.5 million as of March 31, 2021 will be sufficient to fund its operations for at least the next 12 months. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company intends to seek additional capital as it prepares for the launch of Viaskin Peanut, if approved, and continues other research and development efforts. The Company may seek to finance its future cash needs through a combination of public or private equity or debt financings, collaborations, license and development agreements and other forms of <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-dilutive</div> financings. As a result of disruptions to the global financial markets as a result of the ongoing <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, the Company cannot guarantee that it will be able to obtain the necessary financing to meet its needs or to obtain funds at attractive terms and conditions. The ongoing <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has already caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to the Company, including reduced ability to raise additional capital when needed or on acceptable terms, if at all. </div> <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounting Pronouncements adopted in 2021 </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Effective January 1, 2021, the Company adopted ASU <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2019-12, Income</div> Taxes (Topic 740)—Simplifying the Accounting for Income Taxes, which is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. The adoption of ASU <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> did not have a material impact on the Company’s financial position or results of operations. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounting Pronouncements issued not yet adopted </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> - Financial Instruments - Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The FASB has issued ASU <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2019-10</div> which has resulted in the postponement of the effective date of the new guidance for eligible smaller reporting companies to the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. The Company is currently evaluating the impact of the guidance on its Consolidated Financial Statements. The Company does not expect this new standard will have a material impact on its consolidated financial statements. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In January 2017, the FASB issued ASU <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2017-04, Simplifying</div> the Test for Goodwill Impairment, which modifies the goodwill impairment test and requires an entity to write down the carrying value of goodwill for the amount by which the carrying amount of a reporting unit exceeds its fair value. The FASB has issued ASU <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2019-10</div> which has resulted in the postponement of the effective date of the new guidance for eligible smaller reporting companies to the fiscal year beginning January 1, 2023. The Company does not expect this new standard will have a material impact on its consolidated financial statements. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s Consolidated Financial Statements upon adoption. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounting Pronouncements adopted in 2021 </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Effective January 1, 2021, the Company adopted ASU <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2019-12, Income</div> Taxes (Topic 740)—Simplifying the Accounting for Income Taxes, which is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. The adoption of ASU <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> did not have a material impact on the Company’s financial position or results of operations. </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 4: Trade Payables and Other Current Liabilities </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">4.1 Trade Payables </div></div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">No discounting was performed on the trade payables to the extent that the amounts did not present payment terms longer than one year at the end of each fiscal period presented. </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">4.2 Other Current Liabilities </div></div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:76%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">March 31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Employee related liabilities</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9,245</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,661</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Deferred income</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,378</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4,687</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tax liabilities</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">312</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">580</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Other debts</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">460</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">999</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">13,394</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">22,926</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The other current liabilities include short-term debt to employees including employee termination allowance and benefits as part of the restructuring (refer to Note 2, “Significant Events and Transactions of the Period – Restructuring”), bonus accruals, and social welfare and tax agency obligations. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Deferred income primarily includes deferred income from the collaboration agreement with Nestlé Health Science, which amounted to $3.4 million as of March 31, 2021. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:76%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">March 31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December 31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Employee related liabilities</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9,245</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,661</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Deferred income</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,378</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4,687</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tax liabilities</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">312</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">580</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Other debts</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">460</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">999</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">13,394</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">22,926</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 5: Share-Based Payments </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Board of Directors has been authorized by the General Meeting of the Shareholders to grant restricted stock units (“RSU”), stock options plan (“SO”), employee warrants (<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Bons de Souscription de Parts de Créateur d’Entreprise </div>or “BSPCE”) and (<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Bons de Souscription d’Actions</div> or “BSA”). </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March 31, 2021, the Company granted 75,600 stock options and 24,900 restricted stock. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">There have been no changes in the vesting conditions and method of valuation of the SO and RSUs from that disclosed in Note 14 to the consolidated financial statements included in the Annual Report. </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="width:92%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td colspan="4" style="white-space: nowrap; font-size: 8pt;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Stock options fair value assumptions during the three months ended March 31, 2021</div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Weighted average share price at grant date in €</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">9.3</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted average expected volatility</div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">90.9</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">% </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Weighted average risk-free interest rate</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(0.36</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">)% </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted average expected term (in years)</div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Dividend yield</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted average fair value of stock-options in €</div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6.9</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Change in Number of BSA/BCE/SO/RSU </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:67%;"></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:1%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:1%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="14" style="text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">Number of outstanding</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">BSA</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">BCE</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">SO</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">RSUs</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Balance as of December 31, 2020</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">218,008</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">5,500</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">2,610,510</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">1,118,745</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Granted during the period</div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">75,600</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">24,900</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Forfeited during the period</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(15,400</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(13,700</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">) </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Exercised/released during the period</div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(500</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">) </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expired during the period</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance as of March 31, 2021</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">218,008</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">5 000</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">2,670,710</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">1,129,945</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Reconciliation of the share-based payments expenses with the consolidated statements of operations </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="width:79%;"></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:1%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="10" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div><br/><div style="font-weight:bold;display:inline;">March 31,</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">SO</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(376</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(876</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">RSU</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(251</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(392</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing</div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">SO</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(49</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(598</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">RSU</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(22</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">General and administrative</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">SO</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(644</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(1,071</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">RSU</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(91</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(133</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total share-based compensation expense</div></div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,433</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,073</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Change in Number of BSA/BCE/SO/RSU </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:67%;"></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:1%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:1%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="14" style="text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">Number of outstanding</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">BSA</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">BCE</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">SO</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">RSUs</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Balance as of December 31, 2020</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">218,008</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">5,500</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">2,610,510</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">1,118,745</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Granted during the period</div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">75,600</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">24,900</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Forfeited during the period</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(15,400</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(13,700</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">) </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Exercised/released during the period</div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(500</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">) </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expired during the period</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance as of March 31, 2021</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">218,008</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">5 000</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">2,670,710</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">1,129,945</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Reconciliation of the share-based payments expenses with the consolidated statements of operations </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="width:79%;"></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:1%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="10" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div><br/><div style="font-weight:bold;display:inline;">March 31,</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">SO</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(376</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(876</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">RSU</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(251</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(392</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing</div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">SO</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(49</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(598</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">RSU</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(22</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">General and administrative</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">SO</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(644</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(1,071</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">RSU</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(91</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(133</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total share-based compensation expense</div></div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,433</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,073</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 6: Contingencies </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Current contingencies and <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> contingencies break down as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:76%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Current contingencies</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">4,246</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">5,016</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> contingencies</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,229</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,527</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Total contingencies</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,474</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,542</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The table below shows movements in contingencies: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:53%;"></td><td style="vertical-align:bottom;;width:8%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pension retirement</div><br/><div style="font-weight:bold;display:inline;">obligations</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Collaboration</div><br/><div style="font-weight:bold;display:inline;">agreement -</div><br/><div style="font-weight:bold;display:inline;">Loss at</div><br/><div style="font-weight:bold;display:inline;">completion</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other contingencies</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">At January 1, 2021</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">937</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,956</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,649</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,542</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Increases in liabilities</div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Used liabilities</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(434</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(515</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(949</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Reversals of unused liabilities</div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 1pt;"><td style="height:8;"> </td><td colspan="4" style="height:8;"> </td><td colspan="4" style="height:8;"> </td><td colspan="4" style="height:8;"> </td><td colspan="4" style="height:8;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net interest related to employee benefits, and unwinding of discount</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Actuarial gains and losses on defined-benefit plans</div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">85</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">85</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other effects including currency translation effect</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(44</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(164</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">4</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(204</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At March 31, 2021</div></div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">978</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,358</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,139</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,474</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Of which current</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">2,107</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">2,139</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">4,246</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Of which <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-current</div></div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">978</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,251</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,229</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In 2020 and during the first three months of 2021, the ongoing <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic impacted the Company’s current clinical trials, including its Phase II clinical trial conducted as part of the development activities pursuant to the collaboration and license agreement with Nestlé Health Science. The Company experienced a decrease in new patients enrolling in this Phase II clinical trial and modified the protocols of the clinical trial. As a result of these delays, the Company expects to incur additional clinical and production costs related to the Phase II clinical trial. Starting the last quarter of the fiscal year 2020, an accrual in the amount of the difference between the Company’s current best estimates of costs yet to be incurred and revenues yet to be recognized for the completion of the Phase II clinical trial has been recorded. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Other contingencies are primarily composed of the estimated expenses to be incurred as part of the employee-related costs related to restructuring, as well as estimated cost of refurbishing lease premises (Refer to Note 2, “Significant Events and Transactions—Restructuring contingencies). </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">There have been no significant changes in assumptions for the estimation of the retirement commitments from those disclosed in Note 15 to the consolidated financial statements included in the Annual Report. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Current contingencies and <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> contingencies break down as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:76%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Current contingencies</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">4,246</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">5,016</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> contingencies</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,229</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,527</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Total contingencies</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,474</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,542</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The table below shows movements in contingencies: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:53%;"></td><td style="vertical-align:bottom;;width:8%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pension retirement</div><br/><div style="font-weight:bold;display:inline;">obligations</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Collaboration</div><br/><div style="font-weight:bold;display:inline;">agreement -</div><br/><div style="font-weight:bold;display:inline;">Loss at</div><br/><div style="font-weight:bold;display:inline;">completion</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other contingencies</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">At January 1, 2021</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">937</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,956</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,649</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,542</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Increases in liabilities</div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Used liabilities</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(434</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(515</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(949</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Reversals of unused liabilities</div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 1pt;"><td style="height:8;"> </td><td colspan="4" style="height:8;"> </td><td colspan="4" style="height:8;"> </td><td colspan="4" style="height:8;"> </td><td colspan="4" style="height:8;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net interest related to employee benefits, and unwinding of discount</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Actuarial gains and losses on defined-benefit plans</div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">85</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">85</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other effects including currency translation effect</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(44</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(164</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">4</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">(204</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">At March 31, 2021</div></div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">978</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,358</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,139</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,474</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Of which current</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">2,107</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">2,139</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">4,246</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Of which <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-current</div></div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">978</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,251</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,229</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The operating income is broken down in the following manner: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:76%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March 31,</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research tax credit</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">1,807</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">2,902</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Other operating income</div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,133</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,818</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">2,941</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">4,720</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 8: Allocation of Personnel Expenses </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company had an average of 121 employees during the three months ended March 31, 2021, in comparison with an average of 311 employees during the three months ended March 31, 2020. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Allocation of Personnel Expenses by Function: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:80%;"></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="6" style="font-size: 8pt;;text-align:center;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March</div></div></div></div><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;;text-align:center;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31,</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development expenses</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">4,718</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">10,204</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing expenses</div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">518</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">4,197</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">General and administrative expenses</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">3,766</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">4,283</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total personnel expenses</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">9,002</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">18,684</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Allocation of Personnel Expenses by Nature: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:80%;"></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="6" style="font-size: 8pt;;text-align:center;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months Ended March</div></div></div></div><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;;text-align:center;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31,</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Wages and salaries</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">4,454</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">12,872</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Social security contributions</div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,332</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">663</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expenses for pension commitments</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">402</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">915</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Employer contribution to bonus shares</div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,381</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,162</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Share-based payments</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">1,433</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">3,073</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total personnel expenses</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">9,002</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">18,684</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The decrease in personnel expenses is mainly due to a decreased headcount as well as reductions in accrued bonuses, retention measures and share-based compensation expenses, partly as a result of the 2020 global restructuring plan. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Allocation of Personnel Expenses by Function: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:80%;"></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="6" style="font-size: 8pt;;text-align:center;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March</div></div></div></div><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;;text-align:center;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31,</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development expenses</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">4,718</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">10,204</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing expenses</div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">518</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">4,197</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">General and administrative expenses</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">3,766</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">4,283</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total personnel expenses</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">9,002</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">18,684</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Allocation of Personnel Expenses by Nature: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:80%;"></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="6" style="font-size: 8pt;;text-align:center;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months Ended March</div></div></div></div><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;;text-align:center;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31,</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;">  </div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Wages and salaries</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">4,454</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">12,872</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Social security contributions</div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,332</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">663</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expenses for pension commitments</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">402</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">915</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Employer contribution to bonus shares</div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,381</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,162</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Share-based payments</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">1,433</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">3,073</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total personnel expenses</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">9,002</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">18,684</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td><div style="display:inline;"> </div></td><td style="vertical-align:bottom;"><div style="display:inline;">  </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of the ordinary share equivalents that were excluded from the calculation of diluted net loss per share for each of the three months ended March 31, 2021 and 2020 indicated in number of potential shares: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:76%;"></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:2%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended March 31,</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-employee</div> warrants</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">225,008</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">225,008</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Employee warrants</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">75,000</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">82,500</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Stock-options</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,670,710</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2 835,635</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,129,945</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">696,895</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

5000

iso4217:USD xbrli:shares iso4217:EUR xbrli:pure iso4217:EUR xbrli:shares dbvt:patients iso4217:USD xbrli:shares

EX-101.SCH 6 dbvt-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Consolidated Statements of Financial Position link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Consolidated Statements of Financial Position (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 1007 - Disclosure - The Company link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Significant Events and Transactions link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Cash and Cash Equivalents link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Trade Payables and Other Current Liabilities link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Share-Based Payments link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Contingencies link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Operating Income link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Allocation of Personnel Expenses link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Commitments link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Relationships with Related Parties link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Loss Per Share link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Events After the Close of the Fiscal Year link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - The Company (Policies) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Significant Events and Transactions (Tables) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Cash and Cash Equivalents (Tables) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Trade Payables and Other Current Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Share-Based Payments (Tables) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Operating Income (Tables) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Allocation of Personnel Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - The Company - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Significant Events and Transactions - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Significant Events and Transactions - Summary of restructuring reserve (Detail) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Cash and Cash Equivalents - Summary of breakdown of cash and cash equivalents (Detail) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Trade Payables and Other Current Liabilities - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Trade Payables and Other Current Liabilities - Summary of Other Current Liabilities (Detail) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Share-Based Payments - Summary of Stock Options Valuation Assumptions (Detail) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Share-Based Payments - Summary of RSU Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Share-Based Payments - Summary of Share-Based Payments Expenses (Detail) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Share-Based Payments - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Contingencies - Summary of Current Contingencies and Non-current Contingencies (Detail) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Contingencies - Summary of Movement in Contingencies (Detail) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Operating Income - Summary of Operating Income (Detail) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Allocation of Personnel Expenses - Summary of Allocation of Personnel Expenses By Function (Detail) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Allocation of Personnel Expenses -Summary of Allocation of Personnel Expenses By Nature (Detail) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Commitments - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Relationships with Related Parties - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Loss Per Share - Summary of the Common Stock Equivalents Which Were Excluded From the Calculation of Diluted Net Loss Per Share (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 dbvt-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 dbvt-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 dbvt-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Information [Table] Document Information [Line Items] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Interactive Data Current Entity Common Stock, Shares Outstanding Document Transition Report Entity Emerging Growth Company Entity Address, Country Entity Current Reporting Status Entity Shell Company Entity Small Business Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Incorporation, State or Country Code Document Quarterly Report Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Ordinary Shares [Member] Common Shares [Member] Common Stock [Member] Class of Stock [Axis] Class of Stock [Domain] ADR [Member] American Depositary Share [Member] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Net Cash and cash equivalents at the beginning of the period Net cash and cash equivalents at the end of the period Total cash and cash equivalent as reported in statement of financial position Receivables, Net, Current Trade receivables Other Assets, Current Other current assets Assets, Current Total current assets Assets, Noncurrent [Abstract] Non-Current assets Property, Plant and Equipment, Net Property, plant, and equipment, net Operating Lease, Right-of-Use Asset Right-of-use assets related to operating leases Intangible Assets, Net (Excluding Goodwill) Intangible assets Other Assets, Noncurrent Other non-current assets Long-Lived Assets Total non-current assets Assets Total Assets Liabilities and Equity [Abstract] Liabilities and shareholders' equity Liabilities, Current [Abstract] Current liabilities Accounts Payable, Trade, Current Trade payables Operating Lease, Liability, Current Short-term operating lease Short Term Financial Debt Current Short-term financial debt Short term financial debt current. Provision For Liabilities Current Current contingencies Provision for liabilities current. Other Liabilities, Current Other current liabilities Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] Non-Current liabilities Operating Lease, Liability, Noncurrent Long-term operating lease Long Term Financial Debt Noncurrent Long-term financial debt Long term financial debt noncurrent. Provision For Liabilities Noncurrent Non-current contingencies Provision for liabilities noncurrent. Other Liabilities, Noncurrent Other non-current liabilities Liabilities, Noncurrent Total non-current liabilities Stockholders' Equity Attributable to Parent [Abstract] Shareholders' equity Common Stock, Value, Issued Ordinary shares, €0.10 par value; 54,936,687 and 54,929,187 shares authorized, and issued as at March 31, 2021 and December 31, 2020, respectively, and 4,100,663 and 4,029,763 shares outstanding as at March 31, 2021 and December 31, 2020, respectively Additional Paid in Capital Additional paid-in capital Treasury Stock, Value Treasury stock, 60,588 and 112,302 ordinary shares as of March 31, 2021 and December 31, 2020, respectively, at cost Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Accumulated Foreign Currency Translation Adjustment Net of Tax Accumulated currency translation effect Accumulated foreign currency translation adjustment net of tax. Stockholders' Equity Attributable to Parent Total Shareholders' equity Ending balance Beginning balance Liabilities and Equity Total Liabilities and Shareholder's equity Liabilities Total Liabilities Common Stock, Par or Stated Value Per Share Common stock shares par value Common Stock, Shares Authorized Common stock shares authorized Common Stock, Shares, Issued Common stock shares issued Common Stock, Shares, Outstanding Common stock shares outstanding Treasury Stock, Common, Shares Treasury stock, common, shares Income Statement [Abstract] Revenues [Abstract] Revenues Revenues Operating income Operating Expenses [Abstract] Operating expenses Research and Development Expense Research and development expenses Research and development expenses Selling and Marketing Expense Sales and marketing expenses Sales and marketing expenses General and Administrative Expense General and administrative expenses General and administrative expenses Operating Expenses Total Operating expenses Total Operating expenses Operating Income (Loss) Loss from operations Other Nonoperating Income (Expense) [Abstract] Other Income (expenses) Finance Income Expenses Financial income Financial (Expenses). Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before taxes Income Tax Expense (Benefit) Income tax Net Income (Loss) Attributable to Parent Net loss Net loss for the period Net (loss) Earnings Per Share, Basic and Diluted Basic/diluted Net loss per share attributable to shareholders Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average shares outstanding used in computing per share amounts: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation differences, net of taxes Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax Actuarial (loss) gains on employee benefits, net of taxes Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Statement of Cash Flows [Abstract] Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows used in operating activities: Adjustment For Retirement Pension Obligations Retirement pension obligations Adjustment for retirement pension obligations. Share-based Payment Arrangement, Noncash Expense Expenses related to share-based payments Other Noncash Income (Expense) Other elements Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Inventories Decrease (increase) in inventories and work in progress Increase (Decrease) in Accounts Receivable Decrease (increase) in trade receivables Increase (Decrease) in Other Current Assets Decrease (increase) in other current assets Increase (Decrease) in Accounts Payable, Trade (Decrease) increase in trade payables Increase (Decrease) in Other Operating Liabilities (Decrease) increase in other current and non-current liabilities Increase Decrease In Operating Lease Liability And Right Of Use Asset Change in operating lease liabilities and right of use assets Increase decrease in operating lease liability and right of use asset. Adjustment for Depreciation Amortization And Accrued Contingencies Depreciation, amortization and accrued contingencies Adjustment for depreciation, amortization and accrued contingencies. Net Cash Provided by (Used in) Operating Activities Net cash flow used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows used in investing activities : Payments to Acquire Property, Plant, and Equipment Acquisitions of property, plant, and equipment, net from proceeds Payments to Acquire Intangible Assets Acquisitions of intangible assets Payments to Acquire Investments Acquisitions of non-current financial assets Net Cash Provided by (Used in) Investing Activities Net cash flows used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows provided by financing activities : Proceeds from (Repayments of) Other Long-term Debt (Decrease) increase in conditional advances Proceeds from Repayment of Treasury Stock Treasury shares Proceeds from repayment of treasury stock Proceeds from (Payments for) Other Financing Activities Other cash flows related to financing activities Net Cash Provided by (Used in) Financing Activities Net cash flows provided by financing activities Proceeds from Issuance or Sale of Equity Capital increases, net of transaction costs Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rate changes on cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net (decrease) / increase in cash and cash equivalents Equity [Abstract] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Treasury Stock [Member] Treasury Stock [Member] Retained Earnings [Member] Accumulated Deficit [Member] AOCI Attributable to Parent [Member] Accumulated Other Comprehensive income (loss) [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Accumulated Currency Translation Effect [Member] Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) Stock Issued During Period, Value, New Issues Issuance of ordinary shares Stock issued during the period, Value APIC, Share-based Payment Arrangement, Increase for Cost Recognition Share-based payments Shares, Outstanding Beginning balance (Shares) Ending balance (Shares) Stock Issued During Period, Shares, Dividend Reinvestment Plan Issuance of ordinary shares (Shares) Stock Issued During Period, Value, Treasury Stock Reissued Treasury shares Accounting Policies [Abstract] Basis of Presentation and Significant Accounting Policies [Text Block] The Company Significant Events And Transactions Disclosure [Abstract] Significant events and transactions disclosure. Significant Events And Transactions Disclosure Significant Events and Transactions Significant events and transactions disclosure. Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents Disclosure [Text Block] Cash and Cash Equivalents Payables and Accruals [Abstract] Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Trade Payables and Other Current Liabilities Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Text Block] Share-Based Payments Loss Contingency [Abstract] Contingency [Abstract] Contingencies Disclosure [Text Block] Contingencies Other Income and Expenses [Abstract] Other Operating Income and Expense [Text Block] Operating Income Allocation of Personnel Expenses [Text Block] Allocation of Personnel Expenses Allocation of Personnel Expenses Text block Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Relationships with Related Parties Earnings Per Share [Abstract] Loss Per Share [Abstract] Earnings Per Share [Text Block] Loss Per Share Subsequent Events [Abstract] Subsequent Events [Text Block] Events after the Close of the Fiscal Year Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of estimates Going Concern [Policy Text Block] Going concern Going concern. New Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block] Accounting Pronouncements issued not yet adopted New accounting pronouncements not yet adopted, policy. New Accounting Pronouncements, Policy [Policy Text Block] Accounting Pronouncements adopted in 2021 Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Summary of restructuring reserve Schedule of Cash and Cash Equivalents [Table Text Block] Summary of breakdown of cash and cash equivalents Other Liabilities, Current [Abstract] Other Liabilities, Current [Abstract] Other Current Liabilities [Table Text Block] Summary of Other Current Liabilities Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of Stock Options Valuation Assumptions Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Summary of RSU Activity Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Share-Based Payments Expenses Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Summary of Current Contingencies and Non-current Contingencies Schedule of Loss Contingencies by Contingency [Table Text Block] Summary of Movement in Provisions Schedule of operating income Schedule of operating income Schedule of operating income Schedule of Allocation of Personnel Expenses By Function [Table Text Block] Summary of Allocation of Personnel Expenses By Function Schedule of Allocation of Personnel Expenses By Function [Table text block] Schedule of Allocation of Personnel Expenses By Nature [Table Text Block] Summary of Allocation of Personnel Expenses By Nature Schedule of Allocation of Personnel Expenses By Nature[Table text block] Earnings Per Share, Basic and Diluted [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Subsidiary or Equity Method Investee [Table] Consolidated Entities [Axis] Consolidated Entities [Domain] Error Correction, Type [Axis] Error Correction, Type [Domain] Revision of Prior Period [Axis] Revision of Prior Period [Domain] Geographical [Axis] Geographical [Domain] Legal Entity [Axis] Entity [Domain] EX-101.PRE 10 dbvt-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover Page - shares	3 Months Ended
Cover Page - shares	Mar. 31, 2021	Apr. 30, 2021
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Registrant Name	DBV Technologies S.A.
Entity Central Index Key	0001613780
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		54,936,687
Document Quarterly Report	true
Document Transition Report	false
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Address, Country	FR
Entity Small Business	true
Entity Incorporation, State or Country Code	I0
American Depositary Share [Member]
Document Information [Line Items]
Title of 12(b) Security	American Depositary Shares, each representing one-half of one ordinary share, nominal value €0.10 per share
Trading Symbol	dbvt
Security Exchange Name	NYSE
Ordinary Shares [Member]
Document Information [Line Items]
Title of 12(b) Security	Ordinary shares, nominal value €0.10 per share
No Trading Symbol Flag	true
Security Exchange Name	NYSE

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Financial Position - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 152,459	$ 196,352
Trade receivables		2,230
Other current assets	7,349	8,792
Total current assets	159,809	207,375
Non-Current assets
Property, plant, and equipment, net	21,526	24,792
Right-of-use assets related to operating leases	9,168	10,104
Intangible assets	32	41
Other non-current assets	30,870	29,935
Total non-current assets	61,596	64,871
Total Assets	221,405	272,246
Current liabilities
Trade payables	17,176	20,338
Short-term operating lease	3,314	3,708
Short-term financial debt	701	724
Current contingencies	4,246	5,016
Other current liabilities	13,394	22,926
Total current liabilities	38,831	52,713
Non-Current liabilities
Long-term operating lease	9,533	10,496
Long-term financial debt	350	543
Non-current contingencies	2,229	2,527
Other non-current liabilities	1,286	475
Total non-current liabilities	13,398	14,042
Total Liabilities	52,229	66,754
Shareholders' equity
Ordinary shares, €0.10 par value; 54,936,687 and 54,929,187 shares authorized, and issued as at March 31, 2021 and December 31, 2020, respectively, and 4,100,663 and 4,029,763 shares outstanding as at March 31, 2021 and December 31, 2020, respectively	6,519	6,518
Additional paid-in capital	1,153,516	1,152,042
Treasury stock, 60,588 and 112,302 ordinary shares as of March 31, 2021 and December 31, 2020, respectively, at cost	(681)	(1,169)
Accumulated deficit	(987,992)	(958,543)
Accumulated other comprehensive income	399	484
Accumulated currency translation effect	(2,586)	6,158
Total Shareholders' equity	169,176	205,491
Total Liabilities and Shareholder's equity	$ 221,405	$ 272,246

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Financial Position (Parenthetical) - € / shares	Mar. 31, 2021	Dec. 31, 2020
Treasury stock, common, shares	60,588	112,302
Common Shares [Member]
Common stock shares par value	€ 0.10	€ 0.10
Common stock shares authorized	54,936,687	54,929,187
Common stock shares issued	54,936,687	54,929,187
Common stock shares outstanding	4,100,663	4,029,763

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues
Operating income	$ 2,941	$ 4,720
Operating expenses
Research and development expenses	(22,164)	(27,532)
Sales and marketing expenses	(729)	(7,297)
General and administrative expenses	(9,683)	(11,113)
Total Operating expenses	(32,575)	(45,942)
Loss from operations	(29,634)	(41,222)
Other Income (expenses)
Financial income	215	309
Loss before taxes	(29,419)	(40,913)
Income tax	(30)
Net loss	(29,449)	(40,913)
Foreign currency translation differences, net of taxes	(8,744)	(6,064)
Actuarial (loss) gains on employee benefits, net of taxes	(85)	189
Comprehensive loss	$ (38,279)	$ (46,788)
Basic/diluted Net loss per share attributable to shareholders	$ (0.54)	$ (0.79)
Weighted average shares outstanding used in computing per share amounts:	54,880,776	51,802,524

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement of Cash Flows [Abstract]
Net loss for the period	$ (29,449)	$ (40,913)
Cash flows used in operating activities:
Depreciation, amortization and accrued contingencies	1,483	1,548
Retirement pension obligations		109
Expenses related to share-based payments	1,433	3,073
Other elements	(456)	419
Changes in operating assets and liabilities:
Decrease (increase) in inventories and work in progress		(2,402)
Decrease (increase) in trade receivables	2,101
Decrease (increase) in other current assets	(417)	122
(Decrease) increase in trade payables	(2,567)	(3,212)
(Decrease) increase in other current and non-current liabilities	(7,980)	(8,382)
Change in operating lease liabilities and right of use assets	(353)	(45)
Net cash flow used in operating activities	(36,204)	(49,683)
Cash flows used in investing activities :
Acquisitions of property, plant, and equipment, net from proceeds	(184)	(816)
Acquisitions of intangible assets		(114)
Acquisitions of non-current financial assets	(1)
Net cash flows used in investing activities	(185)	(930)
Cash flows provided by financing activities :
(Decrease) increase in conditional advances	(164)	7
Treasury shares	578	(412)
Capital increases, net of transaction costs	42	151,023
Other cash flows related to financing activities	(17)	(7)
Net cash flows provided by financing activities	440	150,611
Effect of exchange rate changes on cash and cash equivalents	(7,944)	(5,811)
Net (decrease) / increase in cash and cash equivalents	(43,893)	94,187
Net Cash and cash equivalents at the beginning of the period	196,352	193,255
Net cash and cash equivalents at the end of the period	$ 152,459	$ 287,442

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Total	Common Shares [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive income (loss) [Member]	Accumulated Currency Translation Effect [Member]
Beginning balance at Dec. 31, 2019	$ 193,186	$ 5,645	$ 1,003,595	$ (230)	$ (798,988)	$ 108	$ (16,945)
Beginning balance (Shares) at Dec. 31, 2019		47,028,510
Net (loss)	(40,913)				(40,913)
Other comprehensive income (loss)	(5,875)					189	(6,064)
Issuance of ordinary shares	151,023	$ 873	150,150
Issuance of ordinary shares (Shares)		7,898,677
Treasury shares	(832)			(832)
Share-based payments	3,073		3,073
Ending balance at Mar. 31, 2020	299,662	$ 6,518	1,156,818	(1,062)	(839,901)	297	(23,009)
Ending balance (Shares) at Mar. 31, 2020		54,927,187
Beginning balance at Dec. 31, 2020	205,491	$ 6,518	1,152,042	(1,169)	(958,543)	484	6,158
Beginning balance (Shares) at Dec. 31, 2020		54,929,187
Net (loss)	(29,449)				(29,449)
Other comprehensive income (loss)	(8,829)					(85)	(8,744)
Issuance of ordinary shares	42	$ 1	42
Issuance of ordinary shares (Shares)		7,500
Treasury shares	488			488
Share-based payments	1,433		1,433
Ending balance at Mar. 31, 2021	$ 169,176	$ 6,519	$ 1,153,516	$ (681)	$ (987,992)	$ 399	$ (2,586)
Ending balance (Shares) at Mar. 31, 2021		54,936,687

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 17 R7.htm IDEA: XBRL DOCUMENT

The Company

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

The Company

Note 1: The Company

™

. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT

™

, a proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin

™

Basis of Presentation

10-K

filed with the SEC on March 17, 2021 (the “Annual Report”). The condensed consolidated statement of financial position at December 31, 2020 was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s critical accounting policies are detailed in the Annual Report. The Company’s critical accounting policies have not changed materially since December 31, 2020.

Use of estimates

On an

on-going

basis, management evaluates its estimates, primarily those related to: (1) evaluation of costs and measure of progress of the development activities conducted as part of the collaboration agreement with Nestlé Health Science, (2) research tax credits, (3) assumptions used in the valuation of right of use assets - operating lease, (4) impairment of

right-of-use

assets related to leases and property, plant and equipment, (5) recoverability of the Company’s net deferred tax assets and related valuation allowance, (6) assumptions used in the valuation model to determine the fair value and vesting conditions of share-based compensation plan and, (7) estimate of contingencies.

Going concern

dit d

’

Imp

t Recherche

). The Company does not generate product revenue and continues to prepare for the potential launch of its first product in the United States and in the European Union, if approved.

Following receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) in connection with its Biologics License Application (“BLA”) for Viaskin

™

Peanut, beginning in August 2020, the Company scaled down its other clinical programs and

pre-clinical

spend to focus on Viaskin

™

Peanut. The Company also initiated a global restructuring plan in June 2020 to provide operational latitude to progress the clinical development and regulatory review of Viaskin

™

Peanut in the United States and European Union. Based on guidance received from the FDA in January 2021, the Company’s plans to implement such guidance, and expected cost savings from implementation of the global restructuring plan, the Company expects that its current balance of cash and cash equivalents of $152.5 million as of March 31, 2021 will be sufficient to fund its operations for at least the next 12 months.

non-dilutive

financings. As a result of disruptions to the global financial markets as a result of the ongoing

COVID-19

pandemic, the Company cannot guarantee that it will be able to obtain the necessary financing to meet its needs or to obtain funds at attractive terms and conditions. The ongoing

COVID-19

pandemic has already caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to the Company, including reduced ability to raise additional capital when needed or on acceptable terms, if at all.

Accounting Pronouncements adopted in 2021

Effective January 1, 2021, the Company adopted ASU

2019-12, Income

Taxes (Topic 740)—Simplifying the Accounting for Income Taxes, which is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. The adoption of ASU

2019-12

did not have a material impact on the Company’s financial position or results of operations.

Accounting Pronouncements issued not yet adopted

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU

2016-13

- Financial Instruments - Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The FASB has issued ASU

2019-10

which has resulted in the postponement of the effective date of the new guidance for eligible smaller reporting companies to the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. The Company is currently evaluating the impact of the guidance on its Consolidated Financial Statements. The Company does not expect this new standard will have a material impact on its consolidated financial statements.

In January 2017, the FASB issued ASU

2017-04, Simplifying

the Test for Goodwill Impairment, which modifies the goodwill impairment test and requires an entity to write down the carrying value of goodwill for the amount by which the carrying amount of a reporting unit exceeds its fair value. The FASB has issued ASU

2019-10

which has resulted in the postponement of the effective date of the new guidance for eligible smaller reporting companies to the fiscal year beginning January 1, 2023. The Company does not expect this new standard will have a material impact on its consolidated financial statements.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Significant Events and Transactions

3 Months Ended

Mar. 31, 2021

Significant Events And Transactions Disclosure [Abstract]

Significant Events and Transactions

Note 2: Significant Events and Transactions

Clinical programs

Viaskin

Peanut for children ages

4-11

On January 13, 2021, the Company received written responses from the FDA to questions provided in the Type A meeting request the Company submitted in October 2020 following the CRL. The Company believes the FDA feedback provides a well-defined regulatory path forward. In exchanges with the FDA, the Company proposed potential resolutions to two main concerns identified by the FDA in the CRL: the impact of patch adhesion and the need for patch modifications. The FDA agreed with the Company’s position that a modified Viaskin Peanut patch should not be considered as a new product entity provided the occlusion chamber of the current Viaskin Peanut patch and the peanut protein dose of 250 µg (approximately 1/1000 one peanut) remains unchanged and performs in the same way it has performed previously. In order to confirm the consistency of efficacy data between the existing and modified patches, the FDA has requested an assessment comparing the uptake of allergen (peanut protein) between the patches in peanut allergic children ages 4 to 11 years. The FDA also recommended conducting a

6-month,

well-controlled safety and adhesion trial to assess the modified Viaskin Peanut patch in the intended patient population.

Viaskin Peanut for children ages

1-3

g dose in this age group, which is the dose being studied in Part B of the study. Enrollment for Part B of EPITOPE was completed in the first quarter of 2021.

Financing

Restructuring

The following table summarizes restructuring activities as of March 31, 2021 included in current contingencies and other current liabilities in the statement of financial position:


	Restructuring liabilities
Restructuring liability - January 1, 2021		9,387
Amounts paid		(4,854	)
Other effect including currency translation effect		(220	)

Restructuring liability - March 31, 2021		4,313

of which current contingencies		1,511
of which other current liabilities		2,803

COVID-19

Pandemic

On March 11, 2020, the World Health Organization declared

COVID-19

a pandemic. This global health crisis led many countries to impose national containment measures and travel bans. In view of this exceptional situation, the Company decided to take all measures aimed primarily at guaranteeing the safety of its employees and the continuation of ongoing clinical trials, in compliance with the directives of the authorities in each country. The Company has experienced a decrease in new patients enrolling in the ongoing clinical studies and it has had to adapt the protocols of its clinical trials because patients remain subject to travel restrictions.

COVID-19

pandemic are presented in the relevant line items of the condensed consolidated statement of financial position and the condensed consolidated statement of operations according to the function or nature of the income or expense.

Legal Proceedings

A class action complaint was filed on January 15, 2019 in the United States District Court for the District of New Jersey, entitled Travis

Ito-Stone

v. DBV Technologies, et al., Case No.

2:19-cv-00525.

The complaint alleged that the Company and its former Chief Executive Officer, its current Chief Executive Officer, and its former Deputy Chief Executive Officer violated certain federal securities laws, specifically under Sections 10(b) and 20(a) of the Exchange Act, and Rule

10b-5

promulgated thereunder. The plaintiffs seek unspecified damages on behalf of a purported class of purchasers of the Company’s securities between February 14, 2018 and March 16, 2020.

The Company believes that the allegations contained in the amended complaint are without merit and will defend the case vigorously.

The Company believes this complaint will not have a material adverse effect on the Company’s consolidated financial position, results of operations or liquidity.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents

3 Months Ended

Mar. 31, 2021

Cash and Cash Equivalents [Abstract]

Cash and Cash Equivalents

Note 3: Cash and Cash Equivalents

The following table presents for each reported period, the breakdown of cash and cash equivalents:


	March 31,		December 31,
	2021		2020
Cash		58,069		42,341
Cash equivalents		94,390		154,011

Total cash and cash equivalents as reported in the statements of financial position		152,459		196,352

Cash equivalents are immediately convertible into cash at no or insignificant cost, on demand. They are measured using level 1 fair value measurements.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Trade Payables and Other Current Liabilities

3 Months Ended

Mar. 31, 2021

Payables and Accruals [Abstract]

Trade Payables and Other Current Liabilities

Note 4: Trade Payables and Other Current Liabilities

4.1 Trade Payables

No discounting was performed on the trade payables to the extent that the amounts did not present payment terms longer than one year at the end of each fiscal period presented.

4.2 Other Current Liabilities

Other current liabilities consisted of the following:


	March 31,		December 31,
	2021		2020
Employee related liabilities		9,245		16,661
Deferred income		3,378		4,687
Tax liabilities		312		580
Other debts		460		999

Total		13,394		22,926

Deferred income primarily includes deferred income from the collaboration agreement with Nestlé Health Science, which amounted to $3.4 million as of March 31, 2021.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Share-Based Payments

3 Months Ended

Mar. 31, 2021

Share-based Payment Arrangement [Abstract]

Share-Based Payments

Note 5: Share-Based Payments

The Board of Directors has been authorized by the General Meeting of the Shareholders to grant restricted stock units (“RSU”), stock options plan (“SO”), employee warrants (

Bons de Souscription de Parts de Créateur d’Entreprise

or “BSPCE”) and (

Bons de Souscription d’Actions

or “BSA”).

During the three months ended March 31, 2021, the Company granted 75,600 stock options and 24,900 restricted stock.

There have been no changes in the vesting conditions and method of valuation of the SO and RSUs from that disclosed in Note 14 to the consolidated financial statements included in the Annual Report.


Stock options fair value assumptions during the three months ended March 31, 2021
Weighted average share price at grant date in €	9.3
Weighted average expected volatility	90.9	%
Weighted average risk-free interest rate	(0.36	)%
Weighted average expected term (in years)	6
Dividend yield	—
Weighted average fair value of stock-options in €	6.9

Change in Number of BSA/BCE/SO/RSU


	Number of outstanding
	BSA		BCE			SO			RSUs
Balance as of December 31, 2020		218,008		5,500			2,610,510			1,118,745
Granted during the period		—		—			75,600			24,900
Forfeited during the period		—		—			(15,400	)		(13,700	)
Exercised/released during the period		—		(500	)		—			—
Expired during the period		—		—			—			—

Balance as of March 31, 2021		218,008		5 000			2,670,710			1,129,945

Reconciliation of the share-based payments expenses with the consolidated statements of operations


	Three Months Ended March 31,
	2021				2020
Research and development		SO	(376	)		(876	)
		RSU	(251	)		(392	)
Sales and marketing		SO	(49	)		(598	)
		RSU	(22	)		(2	)
General and administrative		SO	(644	)		(1,071	)
		RSU	(91	)		(133	)

Total share-based compensation expense			(1,433	)		(3,073	)

XML 22 R12.htm IDEA: XBRL DOCUMENT

Contingencies

3 Months Ended

Mar. 31, 2021

Loss Contingency [Abstract]

Contingencies

Note 6: Contingencies

Current contingencies and

non-current

contingencies break down as follows:


	March 31,		December 31,
	2021		2020
Current contingencies		4,246		5,016
Non-current contingencies		2,229		2,527

Total contingencies		6,474		7,542

The table below shows movements in contingencies:


	Pension retirement obligations			Collaboration agreement - Loss at completion			Other contingencies			Total
At January 1, 2021		937			3,956			2,649			7,542
Increases in liabilities		—			—			—			—
Used liabilities		—			(434	)		(515	)		(949	)
Reversals of unused liabilities		—			—			—			—

Net interest related to employee benefits, and unwinding of discount		—			—			—			—
Actuarial gains and losses on defined-benefit plans		85			—			—			85
Other effects including currency translation effect		(44	)		(164	)		4			(204	)

At March 31, 2021		978			3,358			2,139			6,474

Of which current		—			2,107			2,139			4,246
Of which non-current		978			1,251			—			2,229

In 2020 and during the first three months of 2021, the ongoing

COVID-19

pandemic impacted the Company’s current clinical trials, including its Phase II clinical trial conducted as part of the development activities pursuant to the collaboration and license agreement with Nestlé Health Science. The Company experienced a decrease in new patients enrolling in this Phase II clinical trial and modified the protocols of the clinical trial. As a result of these delays, the Company expects to incur additional clinical and production costs related to the Phase II clinical trial. Starting the last quarter of the fiscal year 2020, an accrual in the amount of the difference between the Company’s current best estimates of costs yet to be incurred and revenues yet to be recognized for the completion of the Phase II clinical trial has been recorded.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Operating Income

3 Months Ended

Mar. 31, 2021

Other Income and Expenses [Abstract]

Operating Income

Note 7: Operating income

The operating income is broken down in the following manner:


	Three Months Ended March 31,
	2021		2020
Research tax credit		1,807		2,902
Other operating income		1,133		1,818

Total		2,941		4,720

XML 24 R14.htm IDEA: XBRL DOCUMENT

Allocation of Personnel Expenses

3 Months Ended

Mar. 31, 2021

Operating Expenses [Abstract]

Allocation of Personnel Expenses

Note 8: Allocation of Personnel Expenses

The Company had an average of 121 employees during the three months ended March 31, 2021, in comparison with an average of 311 employees during the three months ended March 31, 2020.

Allocation of Personnel Expenses by Function:


	Three Months Ended March 31,
	2021		2020
Research and development expenses		4,718		10,204
Sales and marketing expenses		518		4,197
General and administrative expenses		3,766		4,283

Total personnel expenses		9,002		18,684

Allocation of Personnel Expenses by Nature:


	Three months Ended March 31,
	2021		2020
Wages and salaries		4,454		12,872
Social security contributions		1,332		663
Expenses for pension commitments		402		915
Employer contribution to bonus shares		1,381		1,162
Share-based payments		1,433		3,073

Total personnel expenses		9,002		18,684

XML 25 R15.htm IDEA: XBRL DOCUMENT

Commitments

3 Months Ended

Mar. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

Commitments

Note 9: Commitments

There have been no significant changes in other commitments from those disclosed in Note 19 to the consolidated financial statements included in the Annual Report.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Relationships with Related Parties

3 Months Ended

Mar. 31, 2021

Relationships with Related Parties

Note 10: Relationships with Related Parties

XML 27 R17.htm IDEA: XBRL DOCUMENT

Loss Per Share

3 Months Ended

Mar. 31, 2021

Earnings Per Share [Abstract]

Loss Per Share

Note 11: Loss Per Share


	Three Months Ended March 31,
	2021		2020
Non-employee warrants		225,008		225,008
Employee warrants		75,000		82,500
Stock-options		2,670,710		2 835,635
Restricted stock units		1,129,945		696,895

XML 28 R18.htm IDEA: XBRL DOCUMENT

Events After the Close of the Fiscal Year

3 Months Ended

Mar. 31, 2021

Subsequent Events [Abstract]

Events after the Close of the Fiscal Year

Note 12: Events after the Close of the Period

XML 29 R19.htm IDEA: XBRL DOCUMENT

The Company (Policies)

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Basis of Presentation

10-K

Use of estimates

On an

on-going

right-of-use

Going concern

dit d

’

Imp

t Recherche

). The Company does not generate product revenue and continues to prepare for the potential launch of its first product in the United States and in the European Union, if approved.

Following receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) in connection with its Biologics License Application (“BLA”) for Viaskin

™

Peanut, beginning in August 2020, the Company scaled down its other clinical programs and

pre-clinical

spend to focus on Viaskin

™

Peanut. The Company also initiated a global restructuring plan in June 2020 to provide operational latitude to progress the clinical development and regulatory review of Viaskin

™

non-dilutive

financings. As a result of disruptions to the global financial markets as a result of the ongoing

COVID-19

pandemic, the Company cannot guarantee that it will be able to obtain the necessary financing to meet its needs or to obtain funds at attractive terms and conditions. The ongoing

COVID-19

Accounting Pronouncements adopted in 2021

Effective January 1, 2021, the Company adopted ASU

2019-12, Income

2019-12

did not have a material impact on the Company’s financial position or results of operations.

Accounting Pronouncements issued not yet adopted

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU

2016-13

2019-10

In January 2017, the FASB issued ASU

2017-04, Simplifying

2019-10

XML 30 R20.htm IDEA: XBRL DOCUMENT

Significant Events and Transactions (Tables)

3 Months Ended

Mar. 31, 2021

Significant Events And Transactions Disclosure [Abstract]

Summary of restructuring reserve

The following table summarizes restructuring activities as of March 31, 2021 included in current contingencies and other current liabilities in the statement of financial position:


	Restructuring liabilities
Restructuring liability - January 1, 2021		9,387
Amounts paid		(4,854	)
Other effect including currency translation effect		(220	)

Restructuring liability - March 31, 2021		4,313

of which current contingencies		1,511
of which other current liabilities		2,803

XML 31 R21.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents (Tables)

3 Months Ended

Mar. 31, 2021

Cash and Cash Equivalents [Abstract]

Summary of breakdown of cash and cash equivalents

The following table presents for each reported period, the breakdown of cash and cash equivalents:


	March 31,		December 31,
	2021		2020
Cash		58,069		42,341
Cash equivalents		94,390		154,011

Total cash and cash equivalents as reported in the statements of financial position		152,459		196,352

XML 32 R22.htm IDEA: XBRL DOCUMENT

Trade Payables and Other Current Liabilities (Tables)

3 Months Ended

Mar. 31, 2021

Other Liabilities, Current [Abstract]

Summary of Other Current Liabilities

Other current liabilities consisted of the following:


	March 31,		December 31,
	2021		2020
Employee related liabilities		9,245		16,661
Deferred income		3,378		4,687
Tax liabilities		312		580
Other debts		460		999

Total		13,394		22,926

XML 33 R23.htm IDEA: XBRL DOCUMENT

Share-Based Payments (Tables)

3 Months Ended

Mar. 31, 2021

Summary of Stock Options Valuation Assumptions

There have been no changes in the vesting conditions and method of valuation of the SO and RSUs from that disclosed in Note 14 to the consolidated financial statements included in the Annual Report.


Stock options fair value assumptions during the three months ended March 31, 2021
Weighted average share price at grant date in €	9.3
Weighted average expected volatility	90.9	%
Weighted average risk-free interest rate	(0.36	)%
Weighted average expected term (in years)	6
Dividend yield	—
Weighted average fair value of stock-options in €	6.9

Summary of RSU Activity

Change in Number of BSA/BCE/SO/RSU


	Number of outstanding
	BSA		BCE			SO			RSUs
Balance as of December 31, 2020		218,008		5,500			2,610,510			1,118,745
Granted during the period		—		—			75,600			24,900
Forfeited during the period		—		—			(15,400	)		(13,700	)
Exercised/released during the period		—		(500	)		—			—
Expired during the period		—		—			—			—

Balance as of March 31, 2021		218,008		5 000			2,670,710			1,129,945

Summary of Share-Based Payments Expenses

Reconciliation of the share-based payments expenses with the consolidated statements of operations


	Three Months Ended March 31,
	2021				2020
Research and development		SO	(376	)		(876	)
		RSU	(251	)		(392	)
Sales and marketing		SO	(49	)		(598	)
		RSU	(22	)		(2	)
General and administrative		SO	(644	)		(1,071	)
		RSU	(91	)		(133	)

Total share-based compensation expense			(1,433	)		(3,073	)

XML 34 R24.htm IDEA: XBRL DOCUMENT

Contingencies (Tables)

3 Months Ended

Mar. 31, 2021

Loss Contingency [Abstract]

Summary of Current Contingencies and Non-current Contingencies

Current contingencies and

non-current

contingencies break down as follows:


	March 31,		December 31,
	2021		2020
Current contingencies		4,246		5,016
Non-current contingencies		2,229		2,527

Total contingencies		6,474		7,542

Summary of Movement in Provisions

The table below shows movements in contingencies:


	Pension retirement obligations			Collaboration agreement - Loss at completion			Other contingencies			Total
At January 1, 2021		937			3,956			2,649			7,542
Increases in liabilities		—			—			—			—
Used liabilities		—			(434	)		(515	)		(949	)
Reversals of unused liabilities		—			—			—			—

Net interest related to employee benefits, and unwinding of discount		—			—			—			—
Actuarial gains and losses on defined-benefit plans		85			—			—			85
Other effects including currency translation effect		(44	)		(164	)		4			(204	)

At March 31, 2021		978			3,358			2,139			6,474

Of which current		—			2,107			2,139			4,246
Of which non-current		978			1,251			—			2,229

- Definition

Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248

+ Details

XML 35 R25.htm IDEA: XBRL DOCUMENT

Operating Income (Tables)

3 Months Ended

Mar. 31, 2021

Other Income and Expenses [Abstract]

Schedule of operating income

The operating income is broken down in the following manner:


	Three Months Ended March 31,
	2021		2020
Research tax credit		1,807		2,902
Other operating income		1,133		1,818

Total		2,941		4,720

XML 36 R26.htm IDEA: XBRL DOCUMENT

Allocation of Personnel Expenses (Tables)

3 Months Ended

Mar. 31, 2021

Operating Expenses [Abstract]

Summary of Allocation of Personnel Expenses By Function

Allocation of Personnel Expenses by Function:


	Three Months Ended March 31,
	2021		2020
Research and development expenses		4,718		10,204
Sales and marketing expenses		518		4,197
General and administrative expenses		3,766		4,283

Total personnel expenses		9,002		18,684

Summary of Allocation of Personnel Expenses By Nature

Allocation of Personnel Expenses by Nature:


	Three months Ended March 31,
	2021		2020
Wages and salaries		4,454		12,872
Social security contributions		1,332		663
Expenses for pension commitments		402		915
Employer contribution to bonus shares		1,381		1,162
Share-based payments		1,433		3,073

Total personnel expenses		9,002		18,684

XML 37 R27.htm IDEA: XBRL DOCUMENT

Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2021

Earnings Per Share, Basic and Diluted [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]


	Three Months Ended March 31,
	2021		2020
Non-employee warrants		225,008		225,008
Employee warrants		75,000		82,500
Stock-options		2,670,710		2 835,635
Restricted stock units		1,129,945		696,895

XML 38 R28.htm IDEA: XBRL DOCUMENT

The Company - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Subsidiary or Equity Method Investee [Line Items]
Cash and cash equivalents	$ 152,459	$ 196,352	$ 287,442	$ 193,255

XML 39 R29.htm IDEA: XBRL DOCUMENT

Significant Events and Transactions - Additional Information (Detail) $ / shares in Units, $ in Thousands				3 Months Ended
	Mar. 02, 2020 $ / shares shares	Feb. 04, 2020 € / shares shares	Jan. 31, 2020 patients	Mar. 31, 2021 USD ($) patients shares	Mar. 31, 2020 USD ($)	Feb. 04, 2020 $ / shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stockholders' Equity Note, Stock Split, Conversion Ratio		1.0999
Proceeds From Issuance Of Common Stock \| $				$ 150,000
Stock issued during the period, Value \| $				$ 42	$ 151,023
Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues				7,838,687
Public Offering [member] \| Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues		7,500,000		4,874,268
Public Offering [member] \| American Depositary Shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues				9,748,536
Public Offering [member] \| Outside Europe [Member] \| Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues		4,535,581
Public Offering [member] \| Outside Europe [Member] \| American Depositary Shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues		9,071,162
Shares Issued, Price Per Share \| $ / shares						$ 10.25
Over-Allotment Option \| Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues	338,687
Over-Allotment Option \| American Depositary Shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues	677,374
Shares Issued, Price Per Share \| $ / shares	$ 10.25
Global Offering [member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during the period, Value \| $				$ 160,700
Private Placement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares Issued, Price Per Share \| € / shares		€ 18.63
Stock Issued During Period, Shares, Issued for Services		2,964,419
ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage Of Patients Increased ED From Baseline			75.90%
Number Of Patients Increased ED From Baseline \| patients				107
Number Of Patients \| patients				141
Percentage Of Patients Increased ED Of Minimum Thousand Milligram Peanut Protein By Three Year			51.80%	73.00%
Number Of Patients Observed For Safety Profile Till Date \| patients			1,000
Treatment Compliance Percentage			98.00%
Clinical Program Trial Period			6 months
Minimum \| ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Age Of Child			4 years
Maximum \| ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Age Of Child			11 years

XML 40 R30.htm IDEA: XBRL DOCUMENT

Significant Events and Transactions - Summary of restructuring reserve (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($)
Summary of restructuring reserve
Restructuring liability - January 1, 2021	$ 9,387
Amounts paid	(4,854)
Other effect including currency translation effect	(220)
Restructuring liability - March 31, 2021	4,313
of which current contingencies	1,511
of which other current liabilities	$ 2,803

XML 41 R31.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents - Summary of breakdown of cash and cash equivalents (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Cash and Cash Equivalents, at Carrying Value [Abstract]
Cash	$ 58,069	$ 42,341
Cash equivalents	94,390	154,011
Total cash and cash equivalent as reported in statement of financial position	$ 152,459	$ 196,352	$ 287,442	$ 193,255

XML 42 R32.htm IDEA: XBRL DOCUMENT

Trade Payables and Other Current Liabilities - Additional Information (Detail) € in Millions	Mar. 31, 2021 EUR (€)
Nestl Health Science [Member]
Deferred revenues	€ 3.4

XML 43 R33.htm IDEA: XBRL DOCUMENT

Trade Payables and Other Current Liabilities - Summary of Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Other current liabilities	$ 13,394	$ 22,926
Employee related liabilities [Member]
Other current liabilities	9,245	16,661
Deferred income [Member]
Other current liabilities	3,378	4,687
Tax Liabilities [Member]
Other current liabilities	312	580
Other Debts [Member]
Other current liabilities	$ 460	$ 999

XML 44 R34.htm IDEA: XBRL DOCUMENT

Share-Based Payments - Summary of Stock Options Valuation Assumptions (Detail)	3 Months Ended
	Mar. 31, 2021 € / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield
Weighted Average [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average share price at grant date in €	€ 9.3
Weighted average expected volatility	90.90%
Weighted average risk-free interest rate	(0.36%)
Weighted average expected term (in years)	6 years
Weighted average fair value of stock-options in €	€ 6.9

XML 45 R35.htm IDEA: XBRL DOCUMENT

Share-Based Payments - Summary of RSU Activity (Detail)	3 Months Ended
Share-Based Payments - Summary of RSU Activity (Detail)	Mar. 31, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding, Beginning Balance	2,610,510
Number of stock options outstanding, Granted during the period	75,600
Number of stock options outstanding, Forfeited during the period	(15,400)
Number of stock options outstanding, Ending Balance	2,670,710
BSA Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants outstanding, Beginning Balance	218,008
Number of warrants outstanding, Exercised/released during the period	0
Number of warrants outstanding, Ending Balance	218,008
BCE Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants outstanding, Beginning Balance	5,500
Number of warrants outstanding, Exercised/released during the period	(500)
Number of warrants outstanding, Ending Balance	5,000
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of RSU outstanding, Beginning Balance	1,118,745
Number of RSU outstanding, Granted during the period	24,900
Number of RSU outstanding, Forfeited during the period	(13,700)
Number of RSU outstanding, Ending Balance	1,129,945

XML 46 R36.htm IDEA: XBRL DOCUMENT

Share-Based Payments - Summary of Share-Based Payments Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payments	$ (1,433)	$ (3,073)
Research and Development expenses [Member] \| Employee Stock Option Member
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payments	(376)	(876)
Research and Development expenses [Member] \| Restricted Stock Units [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payments	(251)	(392)
Sales and Marketing expenses [Member] \| Employee Stock Option Member
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payments	(49)	(598)
Sales and Marketing expenses [Member] \| Restricted Stock Units [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payments	(22)	(2)
General and Administrative expenses [Member] \| Employee Stock Option Member
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payments	(644)	(1,071)
General and Administrative expenses [Member] \| Restricted Stock Units [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payments	$ (91)	$ (133)

XML 47 R37.htm IDEA: XBRL DOCUMENT

Share-Based Payments - Additional Information (Detail)	3 Months Ended
Share-Based Payments - Additional Information (Detail)	Mar. 31, 2021 shares
Share-Based Payments [Line iteam]
Number of stock options outstanding, Granted during the period	75,600
Share options [Member] \| Employees [Member]
Share-Based Payments [Line iteam]
Number of stock options outstanding, Granted during the period	75,600
Restricted Stock Units [Member]
Share-Based Payments [Line iteam]
Number of RSU outstanding, Granted during the period	24,900
Restricted Stock Units [Member] \| Employees [Member]
Share-Based Payments [Line iteam]
Number of RSU outstanding, Granted during the period	24,900

XML 48 R38.htm IDEA: XBRL DOCUMENT

Contingencies - Summary of Current Contingencies and Non-current Contingencies (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Liability, Defined Benefit Plan [Abstract]
Current contingencies	$ 4,246	$ 5,016
Non-current contingencies	2,229	2,527
Total contingencies	$ 6,474	$ 7,542

XML 49 R39.htm IDEA: XBRL DOCUMENT

Contingencies - Summary of Movement in Contingencies (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Contingencies, Beginning balance	$ 7,542
Increases in liabilities	0
Used liabilities	(949)
Reversals of unused liabilities	0
Net interest related to employee benefits, and unwinding of discount	0
Actuarial gains and losses on defined-benefit plans	85
Other effects including currency translation effect	(204)
Contingencies, Ending balance	6,474
Of which current	4,246	$ 5,016
Of which non-current	2,229	$ 2,527
Pension retirement obligations [Member]
Contingencies, Beginning balance	937
Actuarial gains and losses on defined-benefit plans	85
Other effects including currency translation effect	(44)
Contingencies, Ending balance	978
Of which non-current	978
Collaboration agreement -Loss at completion [Member]
Contingencies, Beginning balance	3,956
Used liabilities	(434)
Other effects including currency translation effect	(164)
Contingencies, Ending balance	3,358
Of which current	2,107
Of which non-current	1,251
Other provisions incl. restructuring [Member]
Contingencies, Beginning balance	2,649
Increases in liabilities	0
Used liabilities	(515)
Other effects including currency translation effect	4
Contingencies, Ending balance	2,139
Of which current	$ 2,139

XML 50 R40.htm IDEA: XBRL DOCUMENT

Operating Income - Summary of Operating Income (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Other Income and Expenses [Abstract]
Research Tax Credit	$ 1,807	$ 2,902
Other Operating income	1,133	1,818
Total	$ 2,941	$ 4,720

XML 51 R41.htm IDEA: XBRL DOCUMENT

Allocation of Personnel Expenses - Summary of Allocation of Personnel Expenses By Function (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Research and development expenses	$ 22,164	$ 27,532
Sales and marketing expenses	729	7,297
General and administrative expenses	9,683	11,113
Total Operating expenses	32,575	45,942
Expenses by Function [Member]
Research and development expenses	4,718	10,204
Sales and marketing expenses	518	4,197
General and administrative expenses	3,766	4,283
Total Operating expenses	$ 9,002	$ 18,684

XML 52 R42.htm IDEA: XBRL DOCUMENT

Allocation of Personnel Expenses -Summary of Allocation of Personnel Expenses By Nature (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based payments	$ (1,433)	$ (3,073)
Total Operating expenses	32,575	45,942
Expenses by Nature [Member]
Wages and salaries	4,454	12,872
Social security contributions	1,332	663
Expenses for pension commitments	402	915
Employer contribution to bonus shares	1,381	1,162
Share-based payments	1,433	3,073
Total Operating expenses	$ 9,002	$ 18,684

XML 53 R43.htm IDEA: XBRL DOCUMENT

Commitments - Additional Information (Detail)	3 Months Ended
Commitments - Additional Information (Detail)	Mar. 31, 2021 USD ($)
Disclosure Of Commitments [Line Items]
Increase (decrease) in other commitments during the period	$ 0

XML 54 R44.htm IDEA: XBRL DOCUMENT

Relationships with Related Parties - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($)
Related Party Transactions [Abstract]
Increase decrease in related party transactions and changes in nature of the transactions	$ 0

XML 55 R45.htm IDEA: XBRL DOCUMENT

Loss Per Share - Summary of the Common Stock Equivalents Which Were Excluded From the Calculation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Non-employee warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	225,008,000	225,008,000
Employee warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	75,000,000	82,500,000
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,670,710,000	2,835,635,000
Restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,129,945,000	696,895,000

EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( .N I5('04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #K@*529]]&B.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)^GBBJ&;B^))07!!\1:2V=U@DX9DI-VW-ZV[740?0,@E,W^^ M^0;2FBA-G_ Y]1$3.EC-N;*#@+>GQY=YW621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M .N I5*KFL*;$04 /P4 8 >&PO=V]R:W-H965T&UL MM5AM;^(X$/Z\]RLL3CK=284D#J5TER)16N[075_I[:E:W0>3&!)M$K.V ^7? MW]B$I*W"A)5NOT!>/(\?STR>&7NP$?*KBCC7Y"5-,G71BK1>?70<%40\9:HC M5CR#-PLA4Z;A5BX=M9*9HR MN;WDB=A> ,!RNVY#.N_U[=2[AS2I0P3GFF8I$1R1<7K9'W M<>Q38V!'?([Y1KVZ)F8I-%R#2.>\$ ;" 9_:S[F26*0@,>W K15 MSFD,7U_OT2=V\;"8.5-\+))_XE!'%ZU^BX1\P?)$/XK-'[Q8T*G!"T2B["_9 M[,9VNRT2Y$J+M# &!FF<[?[92^&(5P9]]X !+0SH.P/OT Q^8>#;A>Z8V65= M,X@8:1,5,)[)X2ZU*OA M,\;-1RMC[M:9OZ'CET[R+9Y_ .]*!#FDKB;3;/?AF 3\\A>,(E/-4_4O,D>W MG*-KY^@VS?&T7?&Z$.#FGMM^0%B/1* M'KWCO''/92Q"DU@$\KO6,3C2/I5^^O"A(1O.2FYGQW&;Q"I@"7GF3)()/*S] M?R1,/HDPD8AES16:=40?AY[F5\KG',!R#WR3X; K:]4+^Y-M:_<.A7-?U M>IY_UGK:C1HYQ6,'SD*R%UG"W) M3#-=GVP-B,_O*\Y;9I5&>_XQS"9Q @5M#)Y:"ED?2QSG5F1M%@30:$@ "7> M&,-*X3UGG;/_5ZO?S9PUG6LJAK@'5D$'G(FP6?) MMLBW6D_A6%KF6%WR*O'WCE3_)Q U%=M6 &&%@S652Z\J !ZNV44$9Q$TQ":. M*Y;5)S\.TTBHDG_O*/V_3KE<&GWX'1!TA%+# 9NHT4KXZ5'"/PI#R&]U IQR M* &UG!J0)H\8H4KO*2[0^^"E#()WF2MXK6JEM &G(_D1D/<@DAJ/5N8PM?[Q;( M=,Z""#;?L.%7L"+S68J,MR.6+,S4< W1!:$W)G8O>$(R 9M.Z$'6+,DY^86E MJT\_]_U>]Y/;\5RR@E)K!V(^J/2>XAH-BAK:5F*;SD52NW0<()RO-<:D$GF* MZ_+>_>3Z)8A8!IOC0\UK ]#M\^P:8U3I.\6%^6X?EZ(J'Y/BE5;3\Q^6XGXE MNSXNEM^1X@U(=V^25/T?6>I78NWC(GLKR-M$/;A5;@!J4&N_4FL?U]/CL[4! MZ%"V.J_.ETP]M\=NB@2F#.R.FLJGY='>R!YH.=7PW;D@;,>A'5 DX0LP=3MG M(&9R=]2VN]%B94^KYD)KD=K+B+.02S, WB^$T/L;,T%YX#G\#U!+ P04 M" #K@*52'LB'/F@& !<&@ & 'AL+W=O'5L=R\O%Y7GSVVUU>2YJ5>0EOZV0K'<[ M5CV_XX5XNEC@QR&^Z\&'[&+A:42\X*G2)AC\>^37O"BT)<#Q M3V=TT<^I%>J>W%(EZ@C&]87:@OXND/WBTHT/92 M45Z))U1I:;"F'QK?--JPFKS4VWBG*GB;@YZZO!9E!IO",P1/4A1YQA0, M[A3\@]U2$HD->I^7K$QS5J!;(?/&_2OT[>X&_?;J=_0*Y27ZNA6U9&4FS]<* M4&G;Z[1#\*Y%0!P(/K'J#%&\1,0CV*)^/:]^P]->W3M47X,O>H>0WB&DL4== M#JFK"M:-F)1)%- KL(*,>9#0;N9]%N3HY>N/>:#R[\ML*&*-2STNT+UBI MEDTDZR#>Z^JP1"57-D?$Y@HAD,.)'RQ2OG.ODAYQ,HNX8:*5V*QJR3L_0$P7 M35E3 NGE,)67#ZC@4/ZMVY@8N!(+/P/I6+E0P[I M-Q-GG8WQY)1,\%ED?.Q -V(+?$*FEA!IQY.A,W4 THLC;XK3%"-)0AW)@( :=X8;.+[PWVU%I5:*5[MIX;""-0L[I=B?8K5(19X+ZE#]<70JU$U_7LOX MO;4^=[8.J-3#4Z 6(>(J< .AX'E&>8FE5)3:FQR .K;>I =_',L=2%,J\+ K MX@<2P?,L M6\0"$F'JP#H0",$G'U).JR9D='*?K_@?1?EPT$&.V/Y8'%F(A\;2Z6*1\USF=#*Q"3FDG_@]82V,!!69Z)+6)^9[O M.%"3@5K(/+6T>#\>P6BR16#;?U,L#*/ 02MDH!42SQ:6NRVK^%84&:_DZZ9# M4<]S565@ G*$":H,4K1Z1E+/()?HUU]B&OIOO3/LP=&E0M#.U_PM"OQE0L-E M&$=-CZ2')%EB&+:*B-4**#K_EV=M%Y5+64-/PN"-0I]8E6[[:Y#F_0TTXKM[ MB.J7VXTE]#%RSYN+K^*Y->(OL>Y9GJ[Q$*=OG$*/6*Q63R3 .:("G MN6X7),[\H0/IT?FNZ6L%+%3K$%(B_;Y$H;<,XKCQ/<9D23V"Q&&4ZU!4.SV4%[T]?4C1WD)8^NI@EJX.C%N[TPA M/W840#IP-9WGZC'HEE;29Z0J5DKX35_9\LT&HL2*VN3D%0D,,K2(09?L2N>! MNNF1)K!AE^/UN\-JX>TP,3M"BQSQ C]Q-.MT(&]Z"GF/R+!)RQ'\UW(.?FA< MW5I;>9N2GAW+L!1>\L @=4[:>,=J#$OOD:<"^4$KOF M<!OH#0_]!Z?(_4$L#!!0 ( .N I5)IEKGZFP( $H' M 8 >&PO=V]R:W-H965T&ULE95=;YLP%(;_BL6D:9.Z M\ UI1Y#65-5V42EJ]G$Q[<(!)U@U-K--TN[7[]A01%H:M3?!QN_[\IQCQ5D)9%JZQK+ATO"Q&'A^,[CBUNZJ[1YX>99@W=D3?2/ M9B5AY@XI):T)5U1P),EVX7SQ+Y:IT5O!3TH.:C1&II*-$'=F\JU<.)X!(HP4 MVB1@>.S)DC!F@@#C;Y_I#)\TQO'X,?W:U@ZU;+ B2\%^T5)7"V?NH))L<>@HE5:U+T9"&K*NR>^[_LP,OC1"X:@-P2O-82] M(;2%=F2VK"NL<9Y)<4#2J"'-#&QOK!NJH=SLXEI+6*7@T_E2\!+VA)0(1DHP M6F(-D[6&!VR65DALT37EF!<4,[02BMKV?UAA".[2YT96A- M,+0FL'G1"WG?X5^A6OF 8!.*NS-4B+H6_.Q$>5U>;//,WV>?)UX\GV?N?ES% MG-4><\< 9OYD3M[H2DOXCY11H_&PCXN@\3))Y^H1V M4AB<^R/A$7(R("=O1J9*M=.XR6MQ)X4G<-,!-WTS+EP,2F->4KZ;8DZ?H40^ MW"])^ 1Y0N<%Y^E(UQ&[HY/.W#)P9.PH5XB1+3B]60H1LCNYNXD6C3W\-D+# M46J'%5QV1!H!K&^%T(\3:D*T(\$ !J M#P & 'AL+W=OO/ 7,-04?R;PE&=/1.CREJ(%_/R);Z= MN0819+#11@3'GP,\0)8928CCOT;HK+W3,)X_GZ1_KI1'9=9N^6HIQ9%(0XW2S$-EFXH;M4D+X\9G+?%K MBGQZ]2"*&)T",<$G);(TYAI?GC7^H+>T(F)+_MF#Y,;JBO#"4.88,HGQY0'( M5Z$4N2(_GC^1BP^7Y -)"_(]$:5"4K5T-((T5SF;!M!]#8B- /+(-U'H1)$_ M$%C\GM]!Y5H-V4G#>S8I\!N7U\2C'PES&;7@>?A]=G<"CM<:W*OD>2/RGN M10EJ0I3?BO(K4?Z(J,8MQ0Y-OA$YV(Q=2YA7$DQ*'U9LX:,9#N<6&!+YH5'V M8 $7M.""23T[T:PD86!Q^QF"%O$X23B9YY!G358)5]@PB UV'"((F2+'E0[46A' M&K5(HTFD?T*!'LLJK#S&4I,J;3R(*3X%.!IB6M8/Z'3>Z@0D^5(5%')QLNCE1/)2ULEFDT;XG!:\V*3H ML_&"U8@X5XS1OI^3?.DQE:QWIC8#6(/S"(A6[* M(%U/H--- <*=*V"3O>*NXTNN33I<6&,?4EV.(;C %80R/>9> / Z"Q@ MF^K?T<72)*)!'@V):#261UTCH=.=Y/U\.!HWT6#JN/(B%@[BQD+GS\,H&H'9 M-0\ZW3WNN4HW3IQFI9EX3R%.L#P3E7"L 5QKF:Y+S=<9YINH3Q.1Q2#M&M7W M1>=(W>M@$#Y6LG#$[*QK,6RZQ?RL5A94A1^PP^R@QHOQ4VJEL:N;#EF:21\' M="PA^[+JF6?JYJ+$@?_&IAH;MIO CR(W#.<][6R4-')9P/KYX9QM+3G(7;7, M*82&*.KQOCUM%\:[:DWJG=_C(EFO?9V8>@O%X7UG4BB#+8I$(R,L62]V]8L6 M^VHW6@N-FU;UF. R#-(0X/>M$/KT8BYHU^O5_U!+ P04 " #L@*52LO)W MQ2X& && & 'AL+W=O=]]O+N/Y,6]5-_TBG.#'M95K2]'*V,VY^.Q+E9\S?1;N>$U_+*4:LT, MO*J[L=XHSDHW:%V-29),QFLFZM'5A?OV25U=R*VI1,T_*:2WZS53CS>\DO>7 M(SPZ?/@L[E;&?AA?76S8';_EYNOFDX*W<3M+*=:\UD+62/'EY>@:G\\IL0.< MQ5^"W^NC9V1#64CYS;[\7EZ.$HN(5[PP=@H&_W9\SJO*S@0XON\G';4^[<#C MY\/L'USP$,R":3Z7U=^B-*O+43Y")5^R;64^R_O?^#Z@S,Y7R$J[O^B^L9W2 M$2JVVLCU?C @6(NZ^<\>]D0<#8!Y_ /(?@#I#T@# ^A^ '6!-LA<6.^885<7 M2MXC9:UA-OO@N'&C(1I1VV6\-0I^%3#.7,UE7<*B\!+!DY:5*)F!EUL#_V"U MC$9RB>9,K] '6'&-SM#7VW?HY,TOZ T2-?JRDEO-ZE)?C V@L7..B[WGF\8S M"7BFZ*.LS4JC]X"@?#I^#%&TH9!#*#G[;\1)VCI)G9,TX.0/*/1*:HV@H)%9<;3A2LC2 MMQK-1!,WD2WNW=49F:7I[&*\.R;)8Y8F,TQ;LR13$^P?KFVMHU97K"$8BO6**G]FF6:(->W3MP<=< M[F&.]ID;&M%D&LBR60MZ%@7])U2 0B 106BS@=>S-)OTH V-4AR@$R==GTWB M%;!BD&VZE_E:K8*\%%CQ\_400&ZKCDZ$77S](MU+NH=D",5 M^'%^KWI"&TD3$N"$=!#):R!"=RPY)%[!Q8XM*G]Y[J<^ MQD1P@@.0NJ:-Z6L@29M9/_^$)\FOQ58I6YO-VGFA44^6X6DORSQ6F(0H[?0 MQP7AY!" A;T/I:44BC;,9^I9XVPR0.TQHP2'<'?Z@+/7X':\HY9RR-=:UF>' M]Z.:\8:4#;%.9WG2#\ECEM,\%%*G0S@N1$W%/RWXR@5VA-O%I.Q>TVX30!MC M>354FS.:]1NKSRK- L%TFH3CHF0W&L5!Q*,:[D4^5*@S.B%)VL?NL4MGDSR@ M"[A3,YS_Z/[#-D+=PXZBK;>3(1S7H>OB^U9HX?3:+BOT5B#*/)ZB3<5J<^H6 MG8/-Q@K5*:J!W*62:VM8I'DAR(2M8'D%M!, MPODZW\_Y%#%. U@Z82-Q8>MC.>X(2U$SV-&Q*E)&Q*-F =T@G921N)0]J8]X MDGDQ#=4,%C?K+:[/:D:3 /9.\TC\I')4')" .P'',;1X/'#Y\@(AG4J15ZD4 M[,E+MZYV_ ^PY1$A/.F7@L=J&J"JDRD2EZDO%NM6/39[83^XH9QDT[R/ MS:,Y:4A%22/J-08G0"0^+GI5[]/U='7O## M(U&:]C MK'[M6!4Z:1&/$$UGZ:!(/699'@J'=H)%XX)EU^.D;+O,N"V)9A,OFFB:EY>& M1#UZEM)\UM^!>>QF*36C6+WFO'2598%-).]&D+Q3-6$ J:JSMWT:RAJV?)B(=J+R6RZI@_LELEOZYM2W4W:+$F: MLT*DO E6YZ//J&/UTX=4"/^2ME6'%R#JI1[SA^KF\_)^0A6C%C&8EFEH.KC MB44LRZI,BL?W)NFH';,*/+Q^R7Y9%Z^*N:>"13S[.TWDZGP4CD#"EG23R:]\ M>\V:@G"5+^:9J/^#;8.%(Q!OA.1Y$ZP8Y&FQ^Z0_FD8NC<<4DS2U@T'!;Q/.<-.0'^ M^<+R>U;^:\DS'\[S*4G2:DG1#-S0-!FK8B*Z3A6GH:2+(S6I/45LRF?55!X_ M#B6Z/,(NCC?Y)JLG:,Z6:9S*H6Q7K\_VIURQ4BD@5_O?JMJ8GIB:R)CG#)QD M7(C3H7&N7S].M"E+5L3/X*ZDA5#?5=O78KE4&UG/"!.EYU;43BMJIQ[2ZQGR M@CVD19$6#VI;RV@1,T"EZEA\!EST.W @(C9E[G+Z=*BT)].G@Z5 M:,*P[^$N:&[)!:&+B89;F+BQX\(NZ-(""DA(PK"+N[(-JF&N+;F03P[X=QKN MM@UW?[+A)[NU>/J:SD>[Y/B E!= )\0(VFEY+2UOD-8?ZNS?Z=H+_6T^K;YN< X--H%:K'P1V.F%+)QRDTYXC_2T-S6D-74?;P95-'$20]?3\PF.AG^GYX,!R;@*A)?4@*>\0)4-BSEM#>(J"W>80>13AF M*Z&BA'1%F.>L31%F-J4(!WKZDK4 QTB=V[HB+#""0^RYNB),H!=ZNB),D(]P MV-/XO55 [^05>B1AFH5*$J1?$GNW@-YB%Y#%"#C$\XQ).(KKTML[!O0++ .R MG/1AZ!!=$#88U@5A P5>CVM >]N WM4W(/.TUQ=,A$S7@/3%-YBF6\K>,:!? M8QF0Q3-@V.-?T-XQH#=;!F3: 4]_LE@< 779[3T#>A_3@$Q#@#Q7=PW'4-TG MR;UM<-YB&Y#U0=*T VJO1H'Q)&FU#=K2G-NR(>QBI*5;6(!CY2[TATD+BH0! M(=H2NK( E;G0'R-#CO8AIL[8\UYE^D(8F^GS[=Y/'.NL^^5"J(+W5E_,FH M#*%Y.YOYK%2U]%/;*(,GA76U#+ATVYEOG)(Y"]75;#F?OYK54IO1Z3'?NW*G MQ[8-E3;JR@G?UK5T]VM5V=W):#'J;ESK;1GHQNSTN)%;=:/";7/E<#7KM>2Z M5L9K:X13QG=GJ/SH/Y5 MXOF!]&6V\OQ7[.+9 UC,6A]LG81Q76L3_\LO*0\#@3?S9P2626#)?D=#[.6Y M#/+TV-F=<'0:VN@'A\K2<$X;*LI-<'BJ(1=.?R^5.+-U(\W]\2Q (=V>94EX M'867SP@?B/?6A-*+GTRN\H?R,SC2>[/LO%DO7U3X7KJI.%B,Q7*^7+R@[Z"/ M[H#U'3RC;Y5EMC5!FZVXLI7.M/+BC]7&!PP"$;./S_TO>B,/7; M6]_(3)V,T%!>N3LU.OW-!B46;\5 L[@TF76-=3*H7&B#[,R7HD7.G0@X5LF= M%[80%TZ:3(W%^?JC^%UEI;&5W5+(-]/55'SW[3=OELOYT>.G8[Z_.!(V:DO' MDNWTBJ60@GA(P4D'O1RW]9^0+CAZ^61[][?]:>LV9NZ+TFR"9*"CSF45V#?F& M7Q[0R3GWA39(,<(2"#(HD%-@^3 HEC2H$6[O2EM5]Q.[,Q#T[<;K7$M'Y9!. MH7JRS37II/.EO%-BHY01 $*#YUQF"?2ZG&H*4@BEV"J#1$ I/5$-"^\!WC@- MUYH*!B!+'MT:-G!#KOJ^_K?3FZGX>;6ZZLM''I!/3"%:&UC)=,N1XAA1U%]51^'J1DGP!5:= <9YM@T6LC+U;&M%"4O(%)&CMB,9_\2YPI M%S!@(1G',,\S6"FL#:1!51H>LGC4W%+W:'[G7C=/AKJIC&&CQIFK7-,%$.!7:FSDM ^[LI ;$+YA&@M#:B+3HZ%49GR'GN*"%844A-0 MV",60IXQ]OO>[P)O\-?FC-,GT]&)4;>A;KT1S=7*T5NTHY#6[B2, Y#J"]B4 MLY-HN&B1B0)%A])[)9U0D$:LYU!8;S 7NB'*Q$UMQRP*N=!2IR<_;ST;4\A@ MS21!#191$4'VD-MZJ'Y-[9SZJ]6$2U+4/C(X%M)C'VPB71"D/[7Y-@J&4@8A MBP*1IYQ38Q#IU9%NH C2BLI::;G1E0Z:54+-L"%P#FX22* WB?"A@920T0@% MTD7]OW7Z$Z[QZ,+,KA6?H.HA65[DK>M&W I/3/2=NF9&_<%82X9I @U 7D% MZWB0DF;P)S4M'4PU!OM:E_*G _!3:31>AR60F[=&;BHU6"$R[;*V1F10Y1]Z MI>YDU;(O_^B9!&#,UE*,&QJM41'<:0?8KR7&N$99W9 Z>KU3\2$IFD1-CO;J MB2TFA)V?^18*DREGQ(VFR'4D",5^C!_,FE(2R4$Q=UA!\<;A@Y>:B' ?V8XP MBE4E%=EL(XK&E#(I,%*QG"'9@9FA:3=8)2EV'1,F)%Y3G 24%^$1G(F-S[3IPY;"G+@X,CY"J(7*36$Y=U M0P\.#X]$P*C .QID%49%A=*= VJY?!LZN MW_5K0%>-2/T7UL;=Y-RU6['*,90U[*6M,WZEI&E1<(U4-HW#MIE'OPV%FY=6K :XE,,$U]'*MF MDNNJY0%U]N'CY?ED\>/^Q_!-RUF#WUFG*[=-_]ZR7(B?F-%)RZ](+PW8?E0] M6!.3V.KF%D\7/TX6RS&_"(%4T_4+1C6("<(T8^]5Z)5=&O%K:UC!JVCNHJ?U M@3)LS":7#A586_S;PWUULQZ\]+")Y-^KR>(@^35G,RDVW'J=+$'XD=#KR?QP M#!9#D^J"-\5.PP=._F"[][U+3.O[G2QI9"C8QM),QGM2;Y 6-=;5*YA@_+'* MC3%5#SUICX;?/2HE=ORIQU:3>!S_/[1W^V_'JWB1Y/] M\?CIZ;UT>/?T(/H"HO/IZQ]&<>QT%\$V_ EE8T.P-?\L\8Z@'!W <]K#NPLR MT']3._TO4$L#!!0 ( .R I5+:XIWSF@X "XD 8 >&PO=V]R:W-H M965T&ULK5K;HJJV3&FXK\=#(>GYT64I=' MKU[P=_?VU0O3U+DNU;T5KBD*:1]?J]QL7QXE1_&+#WJ]J>F+TUW5O\>FTE9+I0I5.FU)8M7IYM$B>O9[1>E[PAU9;U_M;D"5+8S[3A[?9RZ,Q M*:1RE=8D0>*_!W6E\IP$08V_@\RC]DC:V/\[2G_#ML.6I73JRN1_ZJS>O#RZ M.!*96LDFKS^8[:\JV#,G>:G)'?\KMG[M'(O3QM6F")NA0:%+_[_\$OS0VW Q M_LJ&2=@P8;W]0:SEM:SEJQ?6;(6EU9!&?["IO!O*Z9*"\K&V>*JQKW[U4:]+ MO=*I+&MQ\Z#*V@E99N*3E:63[#CWXK3&0;3\- U"7WNADZ\(G8I;4]8;)V[* M3&6[^T^A8*OE)&KY>O)-@;?2CL0T&8C)>))\0]ZTM7K*\J8_;O5BSVIQK5V: M&]=8)?ZS6+K:XL%_OW'VK#U[QF?/_K\>_Z90*MUGKI*I>GF$VG3*/JBC5^]- MK<3DF?B!$\45)&)%+BIKUE863ORAI?NL2_'I5MPK63:U 2(=*/SS"J4TUHY M,1LFB7A;BM_P'"5-X1D/1+U1XLH4E2P?<5!IFC)5F:B,TU2!HC85J8^2=B@= M)\R*=]0;J]3P44D[$(0YPUPN52[4ESI -9I++_?H C%V[=OQ?W-_=M/-Q]% M;;7,L<5[82(:G&XD(D(7X+O7^,"1>IJG.D \4=F^C^E)QRH_$ M8@4-?5"\0;MQ-4M.L@Q?REJ7_Q+'R?C\-)DE)W14!2]RJFUDUMI!RY6V MXN9:K*PI&$\I%P8MTJP _!9*,3BA, MIBB#!.OL8TFUFQNHHO]1O(@$R@R=0G.Z4>&@[H*'\1#RR,S2"%7!\]7&4BTV M.#)3JH ,JW+.4I*%,VITX'HDWO<^M4O@%&T:=U!IJRICL6@D[B _>(+R"WL4 M X+!]RGE* +!)LI25IO'7'[1SKN=%,T450ITS"BD9%U7IJAX:+E4A"U.+_/' M@\JSY2A$DU,$*:@@)_BRUL-X(AR9]JW]U.Y%6(!67#]6$65:=8L MBI1R=9,]4E9*42"9R*9+)#,G0Z^(&.RZ<]ZA=63H,^B6NFRD#V?6**[/ TZ- M>3@BT'VCEG8/==]<+WJ("S46C%0*R2KNKF..<.A:>,-"$[,E]3U!, J(;^MNJ!B&#H M*$$HX6-R_MP)*'5 IP$D^ ,("M$G<<3?#648!<.JM;09R8Y-8T!HEC=9K&>- M0](ZH%6Z&5*U(7@;14V+@0<\TUCE#?VV\W<\#&V-U6N-5H3,)CJ>-;EZ&AE& M+J4A[2X4_* %X*\$ILR(.M,='UZ# $/RRAL*\Y3"%I[AH"M,;03]R--;.)T4]W5"]ET!:"PF!B9+ M5[=7 ]:K,RC3/H96:@2>TB7TS%XT6H ]4-J1!R933]5W4\^J5&G&8$N93RW, MIYCS;"#:!=E= 5(R(2W:UOOIL4(5M443?+!S#J+(I<5[[A"X)=*72V5EN/KSSIL>-X)L:<.M:358(U5*FGZ,6:'4 XCP?8N[C5H#D;')J1(\4J0UE MUQ;9R@%37XAX$3$,1()E[KH$/'S*)QO[) M?"Q^^2FY2)ZOQ3%CUQ>-85\! )+3A%@<\12_^21P "> H!S;C,6#TQ".N1@$ M)PMB68^^L[CXG,),'0J4*7_D%#$V4\QAX(J5MKX$6@::\E32 AI#R%+56Z7\ M,0I$J8ZEO8L8RG4P01KTH (9X%!RKJ4WLJ6F357+S^P5&7B#.-YUV\F. N&H M;C(2/SX9M?@)5$ K5'130*93]-DF<38LZ!9A0,#R'AV%(S[Y@9Y&_04DX[-' MB$4#PF?U/YZ9]%@*@^#M A7YE!0P(5B2G9@A=<:0%XKMID'-$L6[50!^H 8 MU9J"Q?)N;A?>OK O#*ZT$4?%./?Y#:.5X[2F3NX:BK?V+2B-S9C;Q3JD%U_% MY9'L(#(IPGG(B,B"]Z+C(_;="#V!;3Y;6Z"M4XPL'4JW^ W[!Y&9=>O_1E>H M?;WZMN"9!'/:IP/74Y2AL2&M S_FB@.GTCD=@NW$D\.S5D(;AVA%V]J\-3W= MY3*2^ XS#S$*+P^"6[4Z#D?.#_F R+14F[[^E0G$[T";K<[SB&C([S;Q?9:$ MV:U-+Q;.>>$3"\V:4F2C:(BCU1@\2X;<-M7E3JICJ>=:NZQX+T6VK!+;;R]&07UJ53_8A4X<2F;_"C@F08O>MWVFQX1E?EC2W*" MJ%:"H[1&)J;,\BNSY7Y(LT!W9434D$9MJ_U%E=*< ]S"*/DQ$073.$===^\4 MT,Q7)H:H/IWI-M)ZH#K6)PADA3BBK_2ES ;S MZ7PPOT@.[8I R9/X8'R>#)*SB5@4V(UA25PK9BZTYZ/?$R_4%M98D[/* M[B3L)L[T0'P&4X+UI<$,&ZG!A,&G@['LMJ#U<3?COK$T6_)UW&1P>38;S)++ M)PXG*\L#]D4-+T9G4[9R=Z,XKLV: M(5]W^FH4@OF'[V85HJGIN.>S^[8A,Y5U*O\=UR; M\=Z G!?*>43C8#ON#GK#47!4ZZ:($5Z>=WIMZ-JX;"(/WW<.AIAV9MM' .(Y MYX.+X.&]G?W[E=G@XGPVF)Q=?+_"SV<7@(,S]C[<2N=$#N)575OCG&=+*NLQ MEGWED 0_)V?CT3E=2N9Q8BI5W>WE.,['HW%<,J+;DMHV<=;N$P\-[- <0!G/ MLCN+ =UTTQ\::KAKBS0!Q6CC^P@,FKI&MPG/UU3,3VZD,PRPN:EZ%Y_MA-KQ M@.^_Z7B">BRL)2=X%"ZW6CL]1X-C&[ <7<1+D'Z/,78MRT!/AELR+S6."0IG M/Q862M+K!Q?N1R(K:7S/H?Y?:\S:^!$1&R MB"/I:R*^7-SIZ'&N]/>S1/)U<(3A!AR?YUHNP49KW24FM75V !VQ\EV5WA>$ M17F5 MP4IJ>ON7^_"$5S\^OE[KIH-ILF4[/-L_K"WDL$<8T6[Z.N.FPPNQE-Q M=??'V^LA.DQW49STL?Y/8X$KORJ9@SS>]?*)7GGEDKA3*Z*?G9L^,]SE^KY/ MA$;.JM#+JE[200#(F$Y'8G$@8T@O(F*[(IC?T31-I4VW^2DSA)@>4*4I*C]_ M<(_*'R-:1<#WB?97DZT+9LR-ZS0*5NT68'B+X(NGJ2+M<_LB^V=+?]>%I&Q" M*CS0:Y(P 4;&'>_3HV/?@;CQE$-P"+TQ 0. (%?X5U*^;LD5#/7TMHW;3YN_ M?'4-00>!YIJN+S5B \9^H[3RG)>IE0J3 +_D>M!K8\/-SZ%?$9SV?L-1T-T+_5+%>5[I?\[1 M?MO^&&;A?P/2+?>_I$%^KNF2*E&PO=V]R:W-H965T&ULK57;;MLP#/T5PL]&?$W7!$F MWH;MH4.QZ\.P!\6F8Z&RY$ETTO[]*#EU,VPM,& O-B61YQR*)KTZ&'OO6D2" MATYIMXY:HGZ9)*YJL1-N9GK4?-(8VPGBI=TEKK55,J'4 MLD/MI-%@L5E'%]GRLO3^P>&KQ(,[L<%GLC7FWB_>U^LH]8)0844>0?!KCU>H ME =B&3^/F-%$Z0-/[2?TMR%WSF4K'%X9]4W6U*ZC\PAJ;,2@Z*,YO,-C/G./ M5QGEPA,.HV_Q)H)J<&2Z8S KZ*0>W^+A> \G >?I"P'Y,2 /ND>BH/):D-BL MK#F ]=Z,YHV0:HAF<5+[HGPBRZ>2XVAS)5P+0M<0C)N?@]P+A9K<*B&&]TY) M=82Z'*'R%Z *N#6:6@\:^YPO>+K2/+7\B/5VC*B:8,-.7_N-)7H7Q'+ETO*EQ'W'(.[1ZCS0=# M",427D[G?ZG!F$19-=A+1E)/4)E]!XM27]G4I,YZB'0!OCF)(^CG9:-K(0F M=G84 ]/4/"IU/?,W_Q@@.Q1NL"QT<+X&"O>H((-&2 M,/4P>0?P,_O;=)2=M MW:'=A>'EF'30-';XM#O-QXMQ+#R[C\.5R[5CZ:RCX=!T]F8>@1T'UK@@TX8+<]XM-Z!SQO#7]UQX0FFO\;F%U!+ P04 " #L@*52$]V](Z_R([-LN]:J ^VLB(T/2>E1;CS*O8G/$GYF>@I)-(%X%D=G^))C^(GG2][@>Q7X=9[KE@D# MOU]GQFHJF#_.N$B/+E+O(OV?,GR6W;VS*].P'#T/4M0&AY)[4$4H2/<(!F8:! 4F\*@%97D%)HIAP6K@J M1BXLIA1#?";"_B0?3L3)2:ZHRQB+WH7S5BI![8J"7@&5'+ET-?<1+.,Y/)%J]6: Y%"T M=$^F4MI^<-GVE.ZZ<) _&KF;'O?\O7#)^@;J4L)DCKZ0,I18M=D3?:Q>R<^-K,I[ ^W>+.)Y=/?*]Y"7/&0F]>T97&XZ5"E :YANV M&1EW_34[8!1=P<.I \\67?TP@4S)ECB&5WCBV8S*.26J0U$RW+%BF])"FO4;T1=UQ6\$] MR17OW\5)<@6?D G:>LPY"< )=!6GTNK?#>*E+'V73%-J\T)X)I^";_7G2FX* M_]:2PI,!4*/>^S'GRIJ(^UEPW#U.TNM^@'PS[\/'2:8L#2?_6-'7 &IG0.>EHIL>%L[!\?MB^Q=02P,$% @ [("E M4JHM5HP:!0 APL !D !X;"]W;W)K&ULI5;; M;N,V$/V5@8LN'$!K77W+Q8"=3;=]V&X0[W8?BC[0TM@B(HDJ2=EQO[XSE.PX MR2;8HB\B1*O!-&4I]'Z!A=I=]<+> M8>!.;G++ _[LLA8;7*+]6M]J^O./+)DLL3)25:!Q?=6;A^>+A.V=P1\2=^:D M#QS)2JE[_ODMN^H%[! 6F%IF$-1L\1J+@HG(C;\[SMYQ20:>]@_LO[C8*9:5 M,'BMBF\RL_E5;]*##->B*>R=VOV*73Q#YDM58=P7=JUM$O<@;8Q5902O-Q9+CHLE;K'D?^;T31;>C>>F%BE>]6B[&=1;[,U^5Q9A> [?6P*^Y @+ M)70&:@T?I";A*VT@%P96B+0#&ILK+?\AS&H/EJP_8H5:%/")Y".K#>-XV+'G MJLB0X%;!AA)E:0M2BF1J"4ZR3.^AJ22MVG_WTR2*@HN[Y5?7"R_.O,Y U;SS M#-2%J(YVR\^/9EC6A=HCPDYP,9B-(B!$1DZHQJ1:.@K^OQ7:NHEK_>ZG*(XO MA,5&0\9LX?CBIK(::RT-OL+0V:(.5R;:W*A;!6,K& @_:7Y48"> M,[M692VJ?9L-LAD/O5$0/ M55!E$B3>EB>?Y&G"!-%(]MM@6I%*0YJQ! [)R M:VP)PVZEJLKD(V.)5#E7UJTH&N$".M3JL[.@[!M8:U72H+"029,6BM5!Q$XT M8<*59 1Q&U7(3+!G:UF)*I6D 6-IH!62K-*BR5HP(^95U9#%'=9*VP$LGT2\ M%E([MQ"$H;.]&\[^0W[AFSL\:9Q2H^DN ,,*!"IG2JRV$R![S"Y1)>-1<@'3 M0?P2B0\UNIQO54&)*J3=PS083.'GE[:DEOOW:W9.4D6Y7J!YC7XPB$=P]AW$ MD9W,2^B3,WL4VIS!B#;<5F84'>PE%ADXN447+RE.\D4E=,IX?\CE27 C6\> M:CH,?\2#Y^W3O#T3[3%I$+1)&P?>N$U:-/6FE+0[I+V6D@:?[%AS/HQ+UQCT!#3$VE6W?2G2'NV=?^6%6[I]9*67JXN6Y.+V74;$#S:T5'SR4Y M%L*=FQ(U[63&%L+3U&YZKK0HTJ!4J%[4[X][A9"ZLYR'M7N[G)O**ZGQWH*K MBD+8ETM49K?H##K[A0>YR3TO]);S4FSP$?VW\M[2K'= 266!VDFCP6*VZ*P& M%Y![Q)WKO4/[,G:F!\\N4D7G3X;A H3SPB"ABU>H5(,1&;\U6!V#D>R M8OM_C_Y+\)U\60N'5T;]+E.?+SK3#J28B4KY![/[@HT_(\9+C'+A"[M:-B+A MI'+>%(TR65!(78_BN>&AI3#M'U&(&H4HV%T?%*R\%EXLY];LP+(TH?%/<#5H MDW%2O:5=27I^>66TEWJ#.I'HYCU/D+S12QKURUH].J(^A*\$D#OXK%-, MW^KWR)2#/='>GLOH0\"OPI[#<-"%J!\-/L ;'OP;!KSA$;S?C'/PZN0+_+%: M.V\I&?[\ #T^H,70;K&SO#4>87P!;[#AJK(6 MM8?DS:K0*6BCSY)FE]A+\D#?-298K-$>N.1/_PA,W(WB,8RZ_<$8;EMP43>* M9O0=11-X,EZH?^B-N_$DADEW%$?PE"-XL58(:ZYT<+G9.2C,%JF$O0.IWRI? MP/VAM+VT00K,6LF-X'+EH"DEUL:*NGHW%FN9,P@Q%>Q$42H,VW<^)U_?6E=; MO/+PJ] 5-1S8,S$;3F#8G8W&Y-HXGC4.W.B$NIK#8*J28BV5](SS\T_3:!!] M.CI^QR27+[+-Y; M0T+]22-:9_Q!M%U#C#KH1J-!2Y'+X$;7)<1&9:_NOM]VQ%468_NJR_HXN1Q]?# M6(D1Z9JL[%JZG-U07")D*Q:2[3AYP(R\(<30MJ)N("WJ?WJ4&RTSF0AB]/,V M= F[HFC+<*%[!IZ']JFO.7E])S;"G&3BRTG-FJ*%+@6=)(+$@XE*QP]+,JZ M=]!CIW=.KW5[%V@WX8WB(%1J?9$? M5@_/H%5]^[^*UV\H*I -UZO"C%3[YY-1!VS]+JDGWI3A+; VGEX6X3>GIQQ: M%J#]S)##S80/.#P.EW\#4$L#!!0 ( .R I5)N%IBU2@, !\' 9 M>&PO=V]R:W-H965TNRT/71Z@,"EB#$(L 8V?GUW04I6DYK]]"#*&*Q^][;!7:Y.5IW M[QO$ ^M-GZ;-"%TZS3ULL%6^+GMT-!.;5TK BW=(?6=0U'%H%:G19;]D+9" MF62WB;8;M]O8/FAE\,:![]M6N,=+U/:X3?+D9+A5AR:P(=UM.G' .PR_=C>. M5NF$4JD6C5?6@,-ZFUSDZ\L%^T>'WQ0>_=D[<"9[:^]Y<5UMDXP%H489&$'0 MWU>\0JT9B&3\-6(F$R4'GK^?T'^.N5,N>^'QRNK?516:;;)*H,):]#K[BN+"[I<.G0C*'.#:2-OB)@V$RGNI M'!$N!X3B!802/ED3&@\?3(75\_B4U$R2BI.DR^)5P$_"S:',9U!D1?X*7CFE M6$:\\J440X-N3 ^$J>## UUICQ[^N-C[X.AB_/D*S6*B642:Q?^HY*L(W']K MWPF)VX0:S*/[BLGNLPT(RS4\P:LADR\-@OW>J#SLG;U' Y4]&K(")0^UU=1\ M[-8*8]"M*=@A/CLXH+++9JH[/S*X)171',0#2(>5"I#/5MD2BMF/60%#:?^A M(I_E9K(E^^]R=*[LP*R(%#^JX2@98M"M\[I!D2F+)S]D!UC?1, M=]-0$%Q?@Z234))D!J?H21Q5+QE >.B$"Z> YU+X*FDE^2J!(."!YZA" Y_1 M!_WV35&6[^$C"DVF.ZG02)S':D\I4FIT*?3C'/ZMO=*SH=6B.\31S,=-%1CFUV2= MIO_%,/2>W(=/!]VE@S(>--84FLV7[Q)PPS@>%L%V<03N;:"!&E\;^H*A8P?: MKRUUV;A@@NF;N/L;4$L#!!0 ( .R I5+P3I5:I , 'D( 9 >&PO M=V]R:W-H965TLSMN.Q/9.DV;:' MW6:2;??0Z8&68(L3BE1)*H[_?0'*5KP[FV2GTXO%#^#Q/0 DO-P;^^@:1 _/ MK=)N%37>=XLD<56#K7 3TZ&FG:VQK? TM;O$=19%'9Q:E>1I.DU:(76T7H:U M.[M>FMXKJ?'.@NO;5MC#-2JS7T59=%JXE[O&\T*R7G9BAP_H_^CN+,V2$:66 M+6HGC0:+VU5TE2VN2[8/!G]*W+NS,;"2C3&///FM7D4I$T*%E6<$09\GO$&E M&(AH_'/$C,8CV?%\?$+_$+23EHUP>&/4%UG[9A7-(ZAQ*WKE[\W^5SSJN6"\ MRB@7?F$_V!9%!%7OO&F/SL2@E7KXBN=C',X1DYJ3\N M[4KR\^LKI4PE0H#,%N[0.J,U*KA]IK0[=,O$ MTRELFU1'Q.L!,7\%L8"/1OO&P:VNL?[:/R%V(\7\1/$Z?Q/PH[ 3*+(8\C3/ MWL K1LE%P"M>P?N]0TN*]6X4"7]=;9RW5"%_OX%?COAEP"__QY"^B<@7<^$Z M4>$JHIOGT#YAM/YD/,)\ >\=!Y\;A!O3=D(?H!$U"+H+3Q2"';)#EF> ;:?, M 3M[7 MM3G AUZ'R[T@D0QX7GG?L VH<$_1"\M"UW1YG^A1ZNB)\8 GU#*>97/(TCA/ M2W@0BI;8EEZL1PQ%,UI>D%T99Y++N1DFCT66Y+?OR?]">1GT.*$H;4%O>5%2 M%<3S60X/II+$S&%%J?('RJ[V5FYZ)N$@BXLBA^FT>*% 70&ZXQ--I=!*S]$D M5))QF5W [9!\^Q42> ,;HWL'KA%4SPP\S^@WFQ(%7OJ)']H:.G$8X+*X+ H* M83K[T>!QT==849]RR'7Z'7OI@+N6.E!A(G,2HT<-#36XRO14&<+!GIH&?RW6 M?37$0G)#J6Q/ID$*NIBV/;%E@2V!]/84ZC-%?%WH]"&K)R8Q";6>>- 1@E < M=11..5^4D+:=,AO23#O>$H'A&G5*Z E\[[U*SMI!BW87FIZ#(&?H#./JV%>O MAG;R8CXT92JBG22Y"K?DFDYF%Q'8H=$-$V^ZT%PVQE.K"D,.'5HVH/VMH6?J M..$#QG\;ZW\!4$L#!!0 ( .R I5+)Q/NK50( !<% 9 >&PO=V]R M:W-H965T_0-(L&35L:ODX:H M7::I+QK4PD]LBX9O*NNT(#9=G?K6H2@C2*LTFTY?IUI(D^2KZ-N[?&4[4M+@ MWH'OM!;NYQ:5/:V36?+LN)=U0\&1YJM6U/B ]+G=.[;2D:64&HV7UH##:IUL M9LOM(L3'@"\23_[L#*&2@[6/P?A0KI-I$(0*"PH,@C]'W*%2@8AE_!@XDS%E M )Z?G]G?Q=JYEH/PN+/JJRRI62?7"918B4[1O3V]QZ&>J\!76.7C+YSZV*LL M@:+S9/4 9@5:FOXKGH8^G &NIR\ L@&01=U]HJCR5I#(5\Z>P(5H9@N'6&I$ MLSAIPI_R0(YO)>,HWUFM)7&7R:]28L+@3HL!O.W!V0O@.=Q90XV'MZ;$\D]\ MRD)&-=FSFFUVD?!.N G,9Z\@FV:S"WSSL;IYY)O_NSH0IH0=RY6F1E-(]' K M?:&L[QS"M\W!D^,1^7XAZV+,NHA9%__7TXO@L(1+WXH"UPEOF4=WQ"3_: GA M9@GG]7QJD(4WXHAP0#1@+'A9&UG)0AB"HA%2IE!=V8,#8F-,QQ'WV%I' M$_A;,].S8=7HZKB2GG-UAOJY';WCUF_Z8?\=WC\9/"ZU-!X45@R=3MY<)>#Z M->P-LFT<_8,E7J1X;/CE0A<"^+ZR7/!@A 3C6YC_ E!+ P04 " #L@*52 M^%*O$W@" "/!0 &0 'AL+W=O1S=R1E\)4=C[KWQI=A$ MB1>$"G/R#()?#WB%2GDBEO%KY(RFE!YX>GYF_Q1JYUJ.PN&54=]E0?4FNHR@ MP%)TB@ZF_XQC/1>>+S?*A2?T0^R"@_/.D6E&,"MHI![>XG'LPPG@,GD%D(Z M-.@>$@65'P2);&U-#]9',YL_A%(#FL5)[3_*#5F^E8RC[(!*^/:X6K:.0N/4MX M+>P,%O,WD";I_ S?8BIZ$?@6YXH>*WR"6RNT$^$GW1DV?IY)L]RRK,, M>9;_M;EG.?V0KEPK/[0!S7/C9*5E M*7.AB>,M"/T$>2UTA2!UN-2".B8W9;!> M4)36-.PU#GER7&[ED84Q+.A/$R 3,#G'&B6+H+N46NA<"@6.V,$+@1QC4H+!F:S-Y?1&"'\1\,,FT8N:,A'N!PK'ECHO4!?%\:+G@T?()I!V>_ 5!+ M P04 " #L@*52T?[Y,WP# #+!P &0 'AL+W=OU#<1IBA;H+H*DEX>B#Y0TLHA0 MI):DK/CO.Z0N<;:;/.R+1'+F',X9#H?;3NEG4R%:>*F%-+N@LK;91)')*ZR9 MF:D&)5E*I6MF::J/D6DTLL*#:A&E<7P=U8S+8+_U:P]ZOU6M%5SB@P;3UC73 MYP,*U>V")!@7'OFQLFXAVF\;=L0GM'\V#YIFT<12\!JEX4J"QG(7W":;P\+Y M>X>_.';F8@Q.2:;4LYO\5NR"V 6$ G/K&!C]3GB'0C@B"N/+P!E,6SK@Y7AD M_\5K)RT9,WBGQ-^\L-4N6 =08,E:81]5]RL.>I:.+U?"^"]TO>\\#B!OC57U M *8(:B[[/WL9\G !6+\'2 = ZN/N-_)1_LPLVV^UZD [;V)S R_5HRDX+MVA M/%E-5DXXN_]=&0,/J.&I8AJWD25.9XGR 7_H\>D[^#E\4M)6!NYE@<5;?$2Q M3 &E8T"']$/"3TS/8)Z$D,9I\@'??!(X]WSS=_CNF99<'B]$PC^WF;&:ZN'? M#_@7$__"\R^^.X$?XMVEVYB&Y;@+Z%89U"<,]I^514B2#;QEAP,S/ ?A%AM: M-'Z1&\B9R%O!+!:0G:'@)UZ09K 5@J2+[0',6LVSUK),(%CEC9Z@4J) ;4"5 M?NU.U0V39T?DIIVO:R)F)]1T34&V=49[D[?2M O=Y)Z&"%IK+)-^ZZ+58P04 M*5?%#&[-&_Z.&>!T+0@XL2VH:/B,-G82TG EQ[JFIAXQZ M.R0<(^O59"%-C'J5H9[P53Y__&&=)JN?S'0@,_B#K*42U!==JKB##KUQQ+[- ML%/ 3TQ00"Z5S/81X$LN6I>74JO:P\9RG M^%H44\*&+&U(IN.\;!-?8=T(=2;O-%V&<;R>_O>CH6-:,Z=_Y0PQ MK--P2;\GJ_+G*]4XR0;2\'H5AZLDAA36\V5X/5_"(]*=Y[F+USAG:"4GFB1, MTIOP9K&$ZYOK<'VSA&_UA.BBP=:HC_X9H6NG6FG[7CNM3B_5;=^@7]W[9XZD M'SG%*+ D:#Q;+0/0_=/13ZQJ?+O.E*7F[X<5O;:HG0/92T49'B9N@^G]WO\' M4$L#!!0 ( .R I5*B!RJ-IP( 8& 9 >&PO=V]R:W-H965T@W0'#L O%IF.M MLNA2]2US"J(CK5)LW&XS=IK;1-EO.XMN'EG%IOM,4-@VOK6O'S M&@WM%\DD>5FXU;O*AX5T.6_4#N_0?VHV++-TH!2Z1NLT66 L%\EJ!?MH M\%GCWAV,(2C9$MV'R?MBD8Q#0F@P]X&@Y/.(%VA, $D:#STS&4(&Q\/Q"_TZ M:ASVG@9>36 M#&IMNZ]ZZNMPX' V?L4AZQVRF'<7*&9YJ;Q:SIGVP,%::&$0I49O24[;<"AW MGF57BY]?7CVB]0Y6I4<&7R%<&'((5,;)M7:Y,O 5%<]3+^&"4YKWZ'6'SEY! M3^&&K*\<7-D"B]_]4TESR#5[R76='07>*![!='("V3B;'.%-!^W3R)N^PKMK MMPX?6BD ]&7XMMHZSW)3OA_!SP;\+.)GQTNK_JNTQ]$?R"-,LG,X'F.#K*F MCV&=ZD;99\!'95KEL9 V'-1C1_&5\D!YWC++?L>4FN?54/03L6%J=U7$%\*) M@YSDA*T3)QDY,KJ($4IME%NH89(^,H)UKAQ!"T RJ:9@D.=@^1^:: M%!=!R*5FZ6!B!]+$JX:U@>FX2P>4+:0%!2*=(;PH0)PE@I*?)7!Z9W6I<_6' M2A;E.I@5/Z3'NLR(H9!#D0*V(44K%1+I_Z!M]+=+DQ[T9HV\BR^0$UAK?=>F MP^KPR*VZWOYEWKV0R7)/>FGX0 P].__ E02P,$% @ [("E4E*.S:#K!P 9!0 !D !X M;"]W;W)K&ULK5C;;O)Z?\?EPX*.BM>O\%NS)PIC/?/$VO>R-V2#* M*?&,(/'OD:XISQD(9OQ98_9:E2S8_=V@OPF^PY>%='1M\M]4ZK/+WEE/I+24 M5>[OS/I'JOUYR7B)R5WX*];Q[/&KGD@JYTU1"\."0NGX7WZIX] 1.!L_(3"M M!:;![J@H6'DCO;RZL&8M+)\&&O\(K@9I&*6SQ5D/-7OV8DKDU12KT1 M+VY-KA)%[KN+D03 WA'K:-' >_H";Q9DIA*>Z57HG%3_#Y;.&]1&'\<4'#< M*C@."HZ?4#"73CEAEN+6DB/M)5?=OD >A.$F?.U*F=!EKV0@^TB]_=B"=])M]2I4+B]SDR>;P9FK2'HJH53 MJ9*6XR,MB4K+*E6,R>377BQ;??G$VGX_.'X?U0_#";W8;KR?EWP0*V MJ8Q1B,K#L10N2.N&8I;#9;72:JD2J3T.>+))XW$TP@4@)%X[&;C!P26_9J_V MQ6<).WXYC.D_9=*6CB!:-Y1::P7+C-5 MGL(*P33,YP#[J=*1YT(&?"R-?] 5XIG4T>'4:.-#5I*\2AL+VH!P&B:GYT[, MM*X 5%L#E_"RNR7I, DC&>1&(%UJ6QG@&%ZER26YX2KH* MGPK*D\76EDDG-]N &RM,H7P(@34%^^,H5H4J]BH;BA_-FA[)]NO#S\E>[8F M6T*FG\#?X7X_B"H7ZM]HN(Q>C.XCATEE+3_8$5AG*LFXVOM-&DRI-,<3HH74 MF)A\LB\T)>0W]QO$2?TT:ZG1O.!HQ[C;DK56B M0K92]!8/4T9M3D(Y"I*^E!BW'!T$GA4N*T1BB:0#=$/2"H(T?+T!8+$@VU)\ MGU/%;6<@9B'G*^[TVLX#_/RRY>>7!_GYP05["4DHF&?V4?/S$$*7Q]*,E;Y+ ML&V_/*> +/U9*6X.!JJ^4M@7TF%[*B-G<5]]JM)5%/29]$(NEPA_G7CN3F;> M(G(>@"!-7%NYD@N5*Z\")&"Z78ES,),K%;BU2#C4D1(R*F%'&J__'=WL,8T! MT#>FH'""2PC!P1*=<6WKF715L M^4?+) I&KPS[N.#Y'H%@3M5IP$)ND!VDU7;YJ\4=B@\UT" B6=Y"!V8Y0.T< M:)J3MFE.#I;\#P$4J4W([EUFGB$N[A6'7D6:I!"(_L[$S213/3P+/+/D@,<1 MC'>0V&(N#'LEI@W>/@JY@Q(?%6D7() MNZKD2F0;E=;F<3NO2KFI:]8Y@SKF:@V:>3I+"V;V\HM(,)+8O!?BVHIOOYD> M'9TC65ZDHNY]\;8H^<'Q\;GP&)AXI8(L86#F>!L*^0(/JC+T@ QQR DM=4>N MA+,DWA%&EVU7HNN[=^TRU)1#'(!OC(D;VHVM5F*68C51O-L&CQKQ-S>S5CQN M#9HZ2P.[,E>#[#M#\W1:(F?ZCDNXS$''S^&QZSJ0X M2% ,H>V:F\W_;KOPY-%I:#9']!DC$/&#)H@ELE0>_R6W4K,!N':PY!(+3\9Q M:Y3?DM05$JX0RK*TYI'2R&Z1SBKFMM#R;0X#]:'9Z_ZFCNP& ; MC]=0<+&&ZPF52)=A/!([D5E3K0 +C<6"=\-Z*-0E",M1W8_,F74!XTY*"[]3 MR FOL@M3USN3=5"#U*55V%,7W_X^/9F,'G5_CC M#*;.WN^Y0U&K^3QIK4E/7^^O=WM\@:_Q.T^#[,.W;Q)^2>=Z!VF]C9 MY&NQV?T#GDY>#2;3OG@;1TY]?2 B9VU$SOZCV0K$#_6\2&W(-^;L"\Q!#?O? M#9^K%HZ+GRH=/#^)<7K33NL.&-[&="HMZGIN\&]+(K/[^99%HHHZL">#R5$= MT'%04R<%MTYK31#^2NAT,#[N8S: ^M0RO(4T"!]"27?>'%UK4IC6VWV_1@P- M9DK#J]9BLU7(+P$!JP488*L)D N3*JKQ4A-B5:]@,5[*7@P6PXF7,(TYU&_;RN\[NY+VPS<;_>EJN1I5%NQ?P<>=;[\%&17 MX?L6;YRP.7X$:N^VG]!F\VI7"@,UI"='Q\!3+L(W?M.*%-V7X MCK0PWILB_,SP_DF6#^ YO^,U%ZR@_;!X]1=02P,$% @ [("E4FS]&ULC55-;]LP#/TK MA$\MD-5?R9H%28"D[; -*%:TW788=E!L.A8J2YXD-VU__2C9<=,B"79)))'O M\9$2Z>E&Z0=3(EIXJH0TLZ"TMIZ$HCY5#56<(DW&DQ354P_+U&HS2R(@^W!+5^7UAV$\VG- MUGB']D=]HVD7]BPYKU :KB1H+&;!(IXLA\[?._SDN#$[:W"9K)1Z<)NO^2R( MG" 4F%G'P.CO$2]0"$=$,OYVG$$?T@%WUUOVSSYWRF7%#%XH\8OGMIP%XP!R M+%@C[*W:?,$NGY'CRY0P_A^(G+/&6%5U8%)0<=G^LZ>N#CN <70 D'2 MQ.MN WF5E\RR^52K#6CG36QNX5/U:!+'I;N4.ZO)R@EGYW=\+7G!,R8M7#VB MM :8S.%>,VF8+YR!DWNV$FA.IZ&EB X79AW[LF5/#K"G<*VD+0UBMWV :B"7C?1-IEM-)=KMT/]B/O*?931-?#$U"S#65!W M),'\OD0HE*#N<]S67677@OP%S;O0ODFXY61@QBFC@F=E7W'@,A,-724MZ'5J M316#C*Z8L"@S#Z/R*5NB[NV"LQ47+2G!R ;&,HN5,U*(@DM&6":@5H:[FD_@ M]HVJ78;]EF?X -^8;%P]MUH_#=+Q.2PJU;AKK1G/X60X&(^&< K?O4(L"AH. M75*.KI6:O4*_]B#,4A])NYT!_VD_113L\7MW;$4P9K#F]>($%0:.S M\U$ NAUK[<:JVH^2E;(TF/RRI"\!:N= ]D(IN]VX /VW9?X/4$L#!!0 ( M .R I5*^@))MB ( *@% 9 >&PO=V]R:W-H965T==0=1N1C8&A_0?AON-%G1A-+P'J7A2H+&=AE<)O-5[OR]PW>.6W.P!U=) MI=23,[XVRR!VA%!@;1T"H^4%KU (!T0TGG>8P932!1[N]^B??>U42\4,7BGQ M@S>V6P87 338LHVP]VK[!7?U% ZO5L+X+VQ'WR(.H-X8J_I=,#'HN1Q7]KI[ MAX. BV,!Z2X@];S'1)[E-;.L7&BU!>V\"Y2D\"WC)]!ED20AJGR0F\;"HZ\WC9?Q?]\[(R5M.O\NM$FGQ* MD_LT^9$T#^./#JJ%B@3SU*BM=$:]3^\W^);^O:<^F<))=FX&5N,R($T:U"\8 ME(\=0JL$Z8W+-5C71O"WKD+2,2"K.U+4H+3%!@;47#4A6 K[-YYSH(X0A&O) M-=;85ZBG_KA//+YL<1'&YS/(TS#+D_'H 5F>9C-8DB*/(R3!!Z59>)X4F#F MC3.7GJZQS&+O;XEORR63-2>001GN19\4:9@7,TAFYV%6I/!>5Z,#]?2HUWY& M&*C51MI12-/I-(8N1_6]N8\SC)YES:4!@2V%QF>?B@#T.!=&PZK!:[%2EI3M MMQV-4M3.@>Y;I>S>< FFX5S^ 5!+ P04 " #L@*52,=8A8X4" !Q!0 M&0 'AL+W=ODX^?LN*5EU@-@7\;4SL[O4<'%0^LG4 MB!9>&B'-,JBM;>=A:(H:&V:N5(N23BJE&V9IJ7>A:36RTH,:$291- D;QF6P M6OB]C5XMU-X*+G&CP>R;ANG7-0IU6 9Q<-QXX+O:NHUPM6C9#A_1_F@WFE;A MP%+R!J7A2H+&:AGV6Y0 -,EO#=UJCA=J\U M2@M?.MC_JX""U).X*PZ&76G4QR1B:%;TK:VL"]++%\BP\IY2'O MY)CW.KE(^(WI*TCC$211$E_@2X<^I)XO/R,SF/W\X.JSO?YO?9>9'7.G9N6%;@,R)H&]3,&?4E%SR].[K%09"IC ML71I4!142I [N=S-@1I;U+ZS=UA@DQ/%L0C2;3:]BRES? -$Y@/(WZII286P/9)(+9 M; 9;99F F."S#))D-$LF\-Y5A"[R5! T@H !D !X;"]W;W)K&ULC5;;4N,X$/V5KFSM5J@R\27.C8%4$8:9W8=9*,+,/"MV)U9A M2UY)"?#WVRTG)D!(\6)=W'W4?734TOFC-@^V0'3P5)7*7G0*Y^JS,+19@96P M/5VCHC]+;2KA:&A6H:T-BMP[56681-$PK(14G>FYG[LUTW.]=J54>&O KJM* MF.<9EOKQHA-W=A-WS M =M[@U\2'^U>'SB3A=8///@GO^A$'!"6F#E&$-1L\ K+DH$HC/^VF)UV27;< M[^_0O_G<*9>%L'BER]\R=\5%9]R!')=B7;H[_?@W;O/Q 6:ZM/X+CXUM.NI MMK9.5UMGBJ"2JFG%TY:'/8=Q](%#LG5(?-S-0C[*K\*)Z;G1CV#8FM"XXU/U MWA2<5+PI+$JT)^>AHR78,,RV<+,& M+OD K@\_M'*%A6N58_[:/Z30VOB277RSY"C@#V%ZT(\#2*(D/H+7;_/M>[ST MHWP;\8%>PMSI[ %N:E:'A5^B7 LOE$M+"FUF#Q%P%)_/T)FM1887'3HD%LT& M.]/[ @U"(38("T0%2D-6"+5""U*!*Q V:)U4*\BTRF43D% Y5.@*G7.PFS8\ M&K#'_,9;W,U_6E@:7=&D<)!+FY6:-Y. _]4.(4[!:>]!V%:7,A>.?B^E$BJ3 MH@3K:*+9=ZFR:+&4 T RW*$VLB,4!VLC%"4% 7((?WUQ[@_ M3+_ I-=_[XE/-1UTFMCHDH@JI7N&2=2;P)_O;8VT#Z=+#DXJ1UMC'1A>HQOU M^D,X.>#1HI-Y!5T*YAF%L2WS1%EKF\G3' MY5YR0PKYB,[35N?I9W5.$H%++GY$R2%!'P4Z+.@KKUZOL76U0,/+S.:7X>SJ M.IS?A+SBRP^Z"DACI&N2!1D!&;%ZO7)GHB09LH+8\BMFZ+VV HD@B<=!%(UA M$ PB&@7#. H&<01Q$-.?43J [RP1HGE/=S4:J5]V8M>.!L&00=)@0@W5]"7* MSWEVXT&0DL\)]?K!R/>NG]!DDDY::.B*\?7S8Z#NP/N\Q;U^JJ7Y5 1OV]>\ MO3E5+6D0-:2-HF#4D)9,@@F1=D1@@U9@@T\7TD-W".5&5S<>+*%'D0\K[@ZI M?&5TK%\505\N3A=^Y7JW,FY7IIO4%>\KWUZ]8W$2X:(YA/>^7.W?7^^(94G> M44A^FLMOCAMZU]0,QYKN]D=#5LG8-WP,NLD@YIG^)*%F+NA:;2J[, _H2SZ[ MI1.V&4S&K1=;=_GS'15%6'HGD=,+0%K'$6_\%= =IJF791"-XIWS)&Z4VJ?F M7CNN\7L\9;IB?AH>MUPQ0.KMNWU"XLXAB81[[XP*S*2_FS6N/F%U)(KW$);E&O1%IPC0OJ&;@=.U?+0OMZ WDNP4].M&P ?U? M:KK=M@->H'W&3O\'4$L#!!0 ( .R I5)"AJ_BI@, +(( 9 >&PO M=V]R:W-H965TL=T7;VSX,^Z#83"R<+&62W%S__2C)\:6[)-L7ZXU\2#X41<]V2G\Q-:*% MKXV09A[5UFYOXMB4-3;,7*LM2CI9*]TP2TN]B(="."!RX^\.,^I-.L7#^1[]%Q\[Q;)B!N^4^(-7MIY'DP@J7+-6V$>U>X]= M/-[!4@GCO[ +LJ,L@K(U5C6=,GG0OF.6 M+69:[4 [:4)S$Q^JUR;GN'1)>;*:3CGIV<6=DI;+#GX"_2G<:5!KN&NU1FGA M+;-,5O!1R:ORV.DQNL_:A-(.D@3:?T+=(Q/"O+Q+_T1H-\G,-X4.0I MG"&ZZ(DN_B_1]^H%&^<"E_"@U0MW#\51+L]"'N?RN4:PKAA@Y1XN,+7:&6@Z MD\;9?!/G#3ST+Y7E.CBF5H)OF'M]W-43@JV49N$QVF@,,E?@;R9S?#=;@?[X MDZTI+6^)#.0N+?S*9.LHV"=MFHTA&TR+$65AE$\[KC_(DAYI@]Y5P=F*"VX= MSH\_3-(D_>GD^-E@=53A(L]RN(2+(BG<,"53E_"(+Z@-$\9EI)7M*>53XT=T M^;-(Q%NB3C!+ %8!$A?J%1W]$M?<+H1U55G";:"D=J2D1MRN$B';K(\K,20Q_&$\I@5$\ICDDV[ROFTAEW- M26Y?<'MO2&@X[D1#))#2^EW M^X:\#'WHFWCHYA3;QE$M<$VJP^LQU: .'3(LK-KZKK12EGJ&UL?51-;]LP#/TKA$X;$-1?Z9(%B8&FZ[ > MBA5MMAV&'12;CH7*DBG:%303B7?V_1<"?4!FY5H1N$#RN^EF@_SB-']#XH*O94RYXJ M/4&5P9U6KK9PHTHL7^,CDC5H2P_:ENE9PCMN+B!+1I#&:7*&+QMJS0)?=JI6 M5Z,YU,E5"3<[NML6+?R^6EMGZ(;\.9-F/*09AS3C$VD>:7#*K430%>BAO2*D M?:^K9]G\4,YLRPM<,)HZB^896;ZJ\0TU" MKHY]00:D[15Z@>J'2D@;/AS5< M*30S6-4&\=6_ NIT40^M]I\8'BA9<#N^@\)@*1PDHVD\@73T.4ZA[^8;%.+R24#T\]E;SC=AEE8:T>3%;8U/65H? "=5UJ[@^$3#(]C M_@]02P,$% @ [("E4N@T_28/ P D < !D !X;"]W;W)K&ULK57);MLP$/V5@4XMH$:KEP2V@3A-VA[2!G':'HH>:&EL M$:%(E:3B^.\[I&PY 1H':'N11.K-F^4-AY.-TO>F0K3P6 MIID%E;7,61::H ML&;F1#4HZ<]*Z9I96NIU9!J-K/1&M8C2.!Y&->,RF$W\WHV>351K!9=XH\&T M= ;QXUY\@TNDZ52]V[QJ9P&L0L(!1;6,3!Z/> %"N&(*(Q?.\Z@=^D, MGW[OV:]\[I3+DAF\4.([+VTU#<8!E+ABK;"W:O,1=_GX LEC'_"IL,.A@$4 MK;&JWAE3!#67W9L][NKPQ& W0Q.8^?*K> MFH+CTHFRL)K^'/'E@+-VTEDR9TS MBHH=];RC3E^@SN!:25L9N)0EEL_M(PJSCS7=QSI/CQ)>,WT"61)"&J?)$;ZL MSSWS?-D+?%\:U)2Z7!^R_7&^-%93J_P\PI_W_+GGSU_@7W2-[@K[:IGG6[AJ MI>_4/U7ZJ"-W<,],PPJH'#%Y7=GEP>09WE49\)AA0N8NJK[=[Q'!+ M['Z;R9*:_X$.=4-'U +N6?-PE(PAB<,TSF'!J'4\E@IQC[[6/7) N#Q,3D?P M 24I(3R0E=3EW(G@CNL!G86CX9#PZ3B#.V4)W?0I]:#3,(Y32,;A<)S#$04' MO8*#_ZG@9V9;C7_2[ZB;O]>O<[A7KWY-O>\T9CLY#!-,$P.X1 EP(TNPE=J+KFUC4#L9(*I\D M+NM&J"WJ9TQ@%2R5; V8BE&ZCGB9=0!\>A? MM(^>3,D:]=K?!89":Z7M!F:_VU\WY]V4/<"[NXJ*N^94$H$K,HU/1J2O[N9_ MM["J\3-WJ2Q-&PO=V]R:W-H965T.G6!KO$ MDD@^OB>1S'2O])/)$2T<"B'-+,BM+2=19-(<"V8N58F2+%NE"V9IJW>1*36R MS <5(DKB>! 5C,M@/O5G*SV?JLH*+G&EP51%P?3+$H7:SX).<#RXX[O(5".""B\:O!#-J4+O!T?43_Y+63E@TS>*7$3Y[9?!:, M LAPRRIA[]3^,S9Z^@XO5<+X7]@WOG$ :66L*II@8E!P67_9H;F'_PE(FH#$ M\ZX3>9;7S++Y5*L]:.=-:&[AI?IH(L>E>Y2UU63E%&?G7Y4QL$(-ZYQIA _W M;"/0?)Q&EL"=2Y0V0,L:*'D'J NW2MK,GT) MW4X(29QTSN!U6Z5=C]=]!^^&: I,9G#-164Q@X?%QEA-M?)X M)F6O3=GS*7OOI%Q3"V650%!;6$C+,Y>$BA#6F%::6XYT78=45'1CL-6J@"M5 ME)5EOF IZ%_.\.!?".[Q8&$I5/KT^-9;G>7E&GUB2I;B+*!.-JB?,9C?YPA; M):A+*2-P ^S8J8Z)):O2&9=N;SP3_%7Q9R906D-F9F&/[O25'A>6,I%6HM64 M-3((5WTE::L1:<8 LC0_)K2Y1H2BKBMT=054%60_EH5_.EK$P&7&4^9P MN019%1L")9126>+'F:@SF G<>\S36OT;T^-]4_("BU*H%_).DGX8QZ/V>W,T M[)G6S.D?.D,,HR3LTV=MZ5TN5.DD&TC"P3 .AYT8$AAU^^&@VX<[I"KCJ>-K MG#-4DA-,)^PDXW##UV2ON/$4>"60N/+83\ 70^R>F-5Z8?'1ED:17Z9T^Q'[1S(OE5TP\W& M)6C_3>:_ 5!+ P04 " #L@*52:7F/M5 " "_!0 &0 'AL+W=ODDOMAOS_P2\J$EX[*_^S>6.N2RIAHGDOUANBK%W[9$<5K3FYDENOT.;3V+U,LFU^Y)M@QVB M8U9K(\N6C'')1/.G[^TY'!""^ 0A; GAN82H)43G$N*6$)]+2%J"2]UODX51N,J09]+G LA$EA45._*5W.4YL_6C MG#R(YA+::EY.P5#&KQ#QLIB2RXLK?TZ>0=?3^$?KT?/=C]-G9[L'-1[J/Y]\5(>R*$#J] MZ(3>HEYJEC/L4R(5F;W5S.S((YA"YEB'#6@#0'[_0!9Y,%#J/Y]X1IUGY#SC M$YX3J@N"M2.9'0!Z;B@'88[6LI$:."G[\FS2( GC!'/?'-;L".QF$"7A1]CT M?UAX/8SC?V"S8VI1F"0=K,G;/[C\]FG#VJZ9T(3#"HG]WA ;1C7/11,86;E^ M6$J#W>6&!;ZPH"P UU=2FGU@6ZQ[L]._4$L#!!0 ( .R I5*24U>NO@8 M $4B 9 >&PO=V]R:W-H965T%W82)M+6\6%Q;:".#V6N8Y'R@4)9GB1,W9_R6-X= MM?S6PX7W8CK3YD+G^'#.IOR&ZP_S@8*SSM++6"0\S81,D>*3H]:)_^9MX!F# MXHF/@M]E*\?(O,I0RL_FY')\U/(,(A[SD38N&/Q;\#,>Q\83X/A2.6TMQS2& MJ\7&;*,G\GX'S'6LZ-6MX7&?,+R6+^7=W_RZH4"XV\DXZSX1'?5 MLUX+C?),RZ0R!@2)2,O_[&LU$2L&I,D 5P9X5P-2&9!'!A@W&-#*@#X>(6@P M""J#X/$(?H-!6!F$CPUH@T%4&40%6>7L%M3TF6;'ATK>(66>!F_FH."WL 9& M1&I"\48KN"O 3A_?B&DJ)F+$4HW.%SS5&6+I&-TJEF:LB)8,O48GX[$PQRQ& MEVD9_R:.7O:Y9B)^A5Z@#LIF3/$,B11]2(7.#N B'-_.9)Z!Q^RPHP&N&;0S MJJ"=EM!P [0KIMK(PP<(>]BS(Y2?->[.W.XN^!#O#6".UB=Y]>Y;/&R]OOF#5+ MPKJC#@3=,O+P,O)PX9DT> ;QB-E0*F:T")THB+@I!Y'310"NGE_K&5=(SUB* MUHT^_0T^T:7F2?:? Q%9(B(%(MJ4"UJ./L]D/.8J^QV=?\F%OD?OI.8'J+B% M;N:QT < (EW (R8#WIM$J(O%,9(I!XMCO^WU>KW#SJ(&(5TBI$Z$ R5' MG(\S=*%D@BZS+&?IB*/K"6!*$L!3XOR&7M3%8.D[7,44>/!7CRE88@JVSQH2 M@(6/T3A7(IT"5QS-N1)R?( ^LCCG39""#4@4+^&44;[YB!_X'B;UJ,,EZM") M>FV^/EWQ9,B5*X:BI=]H3Z*ZNT34W8&?RY*??LG/H.+FIDCF _0.6H;BB5KM M*OT'*PQ$7=(-NU$]!;TEL)X[F/-A+$80O!->@/J4E"Q K'PO.[YGRYVW)_SX M*R78?UZ&SJH!UB@J4MM;3Z;SF@=I-Z(X[-9SZ5LU]_%3V3Q)X!)T&*C/YS(3 M&EK>ZKU=-4 JTSU(MH-2-C E-5KWRW8#J:NE MH%5RO[%^T M&UOMQL^LW:=X4[N)HV'"5KJQ6[J;"'I2>F,KT7A?)!I;B<;/+-&G>%.BPR@B M$6U@R2HTWM)Q_U!VGU;>=\UN*]+8W6^_C>60Q9N%P[5RMFI+]J6O)E9ER2Y] M]1-7II7OM75GZ$5-JV5B199L:9256# - 1&S43DC.R@J6=G#V!=%)591R19% MW980C[?C:G=4RC&B54*Z[;!A'X!8326[[%^XA:2Z.Y$ F:L%P*^'&&PH"NZ% ME/H-VS[$*C!Q;U=\%"S[+-+;*W0&MT#J8YA%.54L01< ZFPFXK'B*3J9 LQ3 MKN\XG%S('/B5Z#SF"SC=)<@5G?)ELZ8JQ&,R*;%CMB@VC]%E^E( M<9;!Q)SWRXVS4S@SQG7[O5O&B()VS_O5!=?J,7'K\;OX$,>B MR)$!9VFN3@\/*<[1OYRINB#8 BCPV]W'05!-@-LP(FW/&3W4EA'J M+B,UW%P/,Q GF \C"3=LPO6]>>6)B#FZA;E ?5-WG SVJU'7 ZFIZ%%;E:A[ M:_T6F"I[5EA+S&-1;%M;7FN1N#WVNMNF-B3U5@ES5A2!6FAN?R&" MU9*>N7IO:LL3=9>GAZC^AGY2#:"V*-%]61906Y>H>UEP4HI$,1FUU+G-*;H' M27 R9\L1=9>**_;U)S-G2P_=E_V:P!:;P%ULMC&WQ=SWFZGKK'P_;GY@<<74 M5*09BOD$?'GM"%)0E;]9*$^TG!=?F0^EUC(I#F>&ULG95M3]LP$,>_BA7M!4B#//41M9$H,&V3T!"%[;6; M7!(+Q^YLIX5OO[.39F5-NVEO6MOQW?]WY_-YMI7J19< AKQ67.BY5QJSOO)] MG99047TIUR#P2RY510U.5>'KM0*:.:.*^U$0C/R*,N$E,[?VH)*9K UG AX4 MT7554?6V "ZW(T(1=DV9P9D3F> MA#:J3DVMF"CL#-0&R-DM&,KX.?E F"!/I:PU^M$SWR"DE?+3%FC1 $5'@&)R M+X4I-;D3&63O[7T,KHLPVD6XB$XZO*?JDL3A1Q(%4?B\O"5G'\Y/N(V[Q,7. M;7PL<7_)R F)02,,_.&Q_&5BMJ*MU'U9;EQ/7*N[[FE>#";#0;_HJ!,=G13]9DI0 M!/(<[S'65LKKS*8CK94"D;X18TN54W?'FUU]:*-#M"@*^LG&'=GX/\\':RXM MNZ+KXQD?\ SB,.[GF70\DY,\6(K;DJ%PDQM#4KQ)B(9I8M![%2<'%.$P#/LI MIAW%]-\HI#NX'N:ZZDP1[LAB4^>J#L!OR>2VEV M$RO0/:/)+U!+ P04 " #L@*528^]=R*$" !5!P &0 'AL+W=ONZ*LE(CM65* B'G960.=8PE6M7%9+@U$(Y

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end

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company